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“Nothing in life is to be feared, it is only to be understood. Now is the time to understand 
more, so that we may fear less.”― Marie Curie 
 
ABSTRACT 
Plasmodium falciparum causes human malaria and is a global leading cause of mortality from 
parasitic infections. While decades of concerted effort has yielded significant result in reducing 
the endemicity, there is evidence of a recent resurgence in transmission intensity. 
Notably, Plasmodium falciparum parasites are master adapter to various environmental 
pressures, including stresses mounted by the host immune system as well as assaults from an 
arsenal of anti-malarial drugs. Intuitively, this adept adaptability constitutes a major impedance 
to a continued success in the control program. The mechanisms that confer such a high 
adaptability to parasite is currently unclear, but the plastic AT-rich genome, a versatile but 
enigmatic transcription network as well as the recently characterized cell-cell communication 
module via extracellular vesicles are likely contributors to such cause. Through experimental 
designs that sought to investigate the dynamics of these aforementioned molecular and cellular 
programs on both population and single-cell level, the works presented in this thesis aim to 
further the current understandings on how the parasites respond and adapt to various 
environmental pressures. 
In paper I, we investigated the short-term effect of anti-malarial drugs on the genomic plasticity 
of parasite. We revealed that all the tested anti-malarial drugs can cause acute DNA damages 
and trigger a robust response to the damages by the upregulation of specific DNA repair 
pathways. We further demonstrated that the DNA damages elicited by the drug action can be 
erroneously repaired to incorporate random mutations. Therefore, due to the random nature of 
DNA damages and the subsequent error-prone repair, this can serve as a mechanism to rapidly 
diversify the genetic pools of the exposed parasite population and pre-deposit it to a rapid 
selection of resistant genotypes. 
In paper II, we described the role of extra-cellular vesicles (EVs) during malaria infection. 
Infected RBCs are previously characterized for their enhanced capacity to generate EVs. In this 
study, we discovered that EVs originated from infected cell contain a subset of host miRNAs 
and the Ago2 proteins. These EVs are readily internalized by endothelial cells and that the 
miRNAs trafficked within these EVs can accumulate in the endothelial cells and exert a global 
effect on the post-transcriptional gene regulatory network. We show that this unilateral cellular 
communication can contribute to vascular dysfunction, local and systemic immunological 
modulation as well as endothelial activation. In particular, we note that endothelial activation 
can promote sequestration of infected RBCs and, thereby, serve to avoid splenic clearance. 
In paper III, we developed and detailed a technical platform that enables single-cell 
transcriptomic analysis of individual Plasmodium falciparum parasites. We then utilized the 
method to decipher the transcriptional cascade underlying the process of gametogenesis, which 
is triggered by yet undetermined environmental cues. Interestingly, we revealed huge 
heterogeneity even within a highly synchronous parasite population, supporting the presence 
of a versatile transcriptional network. Moreover, we identified a distinct gene signature that is 
associated with sexually committed and differentiating parasites. This work has generated 
important knowledge that can be exploited for the design of transmission blocking drugs. 
LIST OF SCIENTIFIC PAPERS 
This thesis is based on the following papers: 
 
I. Hjelmqvist D, Hedberg P,Talavera López C, Md Idris Z, Ankarklev J, 
Kirkman L, Diestch K, Ribacke U, Chan S, and Wahlgren M. “Antimalarial 
drugs and DNA damage response in Plasmodium falciparum.” 
Manuscript 
 
 
II. Mantel P-Y, Hjelmqvist D, Walch M, Kharoubi-Hess S, Nilsson S, Ravel D, 
Ribeiro M, Gruring C, Ma S, Padmanabhan P, Trachtenberg A, Ankarklev J, 
Brancucci NM, Huttenhower C, Duraisingh MT, Ghiran I, Kuo WP, Filgueira 
L, Martinelli, Marti M (2016). “Infected erythrocyte-derived extracellular 
vesicles alter vascular function via regulatory Ago2-miRNA complexes in 
malaria.” Nature Communications 7 (1): 12727. 
 
III. Ngara M, Palmkvist M, Sagasser S, Hjelmqvist D, Björklund P K, Wahlgren 
M, Ankarklev J, Sandberg R (2018). "Exploring parasite heterogeneity using 
single-cell RNA-seq reveals a gene signature among sexual stage Plasmodium 
falciparum parasites." Exp Cell Res 371(1): 130-138. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The following publications were also obtained during the course of the PhD 
studies but are not included in this thesis: 
I. Pellé KG, Jiang RH, Mantel PY1, Xiao YP, Hjelmqvist D, Gallego- 
Lopez GM, O T Lau A, Kang BH, Allred DR, Marti M. Shared elements 
of host-targeting pathways among apicomplexan parasites of differing 
lifestyles. Cell Microbiol. 2015 Nov;17 (11): 1618-39. 
 
II. Gulati S, Ekland EH, Ruggles KV, Chan RB, Jayabalasingham B, Zhou 
B, Mantel PY, Lee MCS, Spottiswoode N, Coburn-Flynn O, Hjelmqvist 
D, Worgall TS, Marti M, Paolo GD, and Fidock DA. “Profiling the 
Essential Nature of Lipid Metabolism in Asexual Blood and Gametocyte 
Stages of Plasmodium falciparum.” Cell Host Microbe. 2015 Sep 9; 
18(3): 371–381. 
INNEHÅLLSFÖRTECKNING 
1 INTRODUCTION .......................................................................................................... 1 
1.1 Malaria and Public health ..................................................................................... 1 
1.2 The Plasmodium Parasite and the life cycle ...................................................... 1 
1.3 Pathogenesis of Plasmodium falciparum malaria ............................................. 3 
1.3.1 Uncomplicated malaria. ..................................................................................... 4 
1.3.2 Severe malaria .................................................................................................... 4 
1.4 Malaria treatment – Antimalarial drugs ............................................................... 4 
1.4.1 Amodiaquine (AQ), Chloroquine (CQ) and Piperquine (PPQ) .......................... 5 
1.4.2 Artemesinin (ART), Artesunate (ATS) and Dihydroartemisinin (DHA) ........... 6 
1.5 Resistance to antimalarial drugs ....................................................................... 7 
1.5.1 Antimalarial drugs mode of action and resistance mechanism ........... 7 
1.6 Plasmodium falciparum Genome ......................................................................... 8 
1.7 DNA Damage and Repair ................................................................................... 11 
1.8 DNA Repair Pathways .................................................................................... 12 
1.9 Extracellular Vesicles (EVs) ............................................................................... 14 
1.10 Different Types of EVs ....................................................................................... 16 
1.10.1 Exosomes ............................................................................................ 17 
1.10.2 Microvesicles (MVs) ........................................................................... 17 
1.10.3 Apoptotic Bodies (ABs) ...................................................................... 18 
1.11 Biogenesis, composition and function of extracellular vesicles .................... 18 
1.12 The role of EVs in malaria disease ............................................................................. 20 
1.13 Argonaute2 (Ago2) and miRNA ..................................................................... 21 
1.14 Single Cell Technology ................................................................................... 22 
1.15 Single-Cell gene expression analysis .............................................................. 22 
1.16 Singe Cell RNA Sequencing (scRNA-seq) ........................................................ 23 
2 AIM ............................................................................................................................... 25 
3 RESULTS AND DISCUSSION ................................................................................... 35 
4 CONCLUSION AND FUTURE PERSPECTIVES ............................................................ 44 
5 ACKNOWLEDGEMENTS ..................................................................................... 46 
6 REFERENCES ........................................................................................................ 49 
LIST OF ABBREVIATIONS 
 
A-NHEJ Alternative-non homologous end joining 
AB Apoptotic body 
ADR Adverse drug reaction 
AQ Amodiaquine 
ARMD Accelerated resistance to multiple drugs 
ART Artemisinin 
ATS Artesunate 
BER Base excision repair 
BMEC Bone marrow-derived endothelial cell 
C-NHEJ Canonical-non homologous end joining 
CDC Centre of disease control 
CNV Copy number variants 
CQ Chloroquine 
DDI Drug –drug interaction 
DCF-DA Dihydrodichlorofluorescein diacetate 
DHA Dihydroartemisinin 
DSB Double-strand break 
EM Electron microscopy 
EV Extracellular vesicle 
EXP Exported protein 
GSH Glutathione 
HR Homologous recombination 
HRR Homologous recombination repair 
iRBC infected red blood cell 
IDC Intraerythrocytic cycle 
IFA Immunofluorescence assay 
INDEL Small insertions and deletions 
miRNA Micro RNA 
MAC Magnetic-activated cell sorting 
MDA Mass drug administration 
MMEJ Micro-homology end joining 
MMR Mismatch repair 
MP Micro-particles 
MV Micro-vesicles 
NER Nucleotide excision repair 
NGS Next generation sequencing 
NHEJ Non-homologous end joining 
OTM Olive tail moment 
PPQ Piperaquine 
RBC Red blood cell 
RISC RNA-induced silencing complex 
RNAi RNA interference 
ROS Reactive oxygen species 
scRNA-seq Single cell RNA sequencing 
SNP Single nucleotide polymorphism 
SV Structural variants 
TCA Tricarboxylic acid 
TEER Transepithelial electrical resistance 
UPR Unfolded protein response 
WHO World Health Organization 
1  
1 INTRODUCTION 
 
1.1 MALARIA AND PUBLIC HEALTH 
Malaria remains one of the most devastating infectious diseases in the tropics, although global 
eradication efforts in the past decade have decreased the number of deaths. There is still an 
estimated 219 million cases and 435 000 related deaths of malaria in 2017 according to the 
WHO´s 11th World Malaria Report (WHO, 2018). These deaths are primarily cause by 
Plasmodium falciparum in African children under five years of age and pregnant women. 
Mortality among young children is due to severe malaria. 
Cerebral malaria, hypoglycemia and severe anaemia are the common features of severe 
malaria. Malaria is a disease of poverty and the impact of malaria takes its toll mostly in poor, 
tropical and subtropical areas of the world. African countries bear the heaviest burden of 
malaria due to Anopheles gambiae mosquito which is responsible for high transmission 
according to the Centers for Disease Control and Prevention (CDC) and WHO. 
Malaria is still one of the most important challenges to global public health and in order to be 
ultimately controlled and eliminated, the economic and social conditions need to be 
addressed. Moreover, the development of resistance to antimalarial drugs also compromises 
control and elimination strategy. 
 
1.2 THE PLASMODIUM PARASITE AND THE LIFE CYCLE 
Parasitic infections of the erythrocytes are among the most common and oldest infections in 
vertebrates. Malaria is caused by protozoan parasites called Plasmodia that belong to the 
apicomplexa parasites. Plasmodium is a genus of unicellular eukaryotes and has a complex 
and multistage life cycle occurring within two hosts, the vector mosquitoes and the human 
hosts. There are more than 250 species of Plasmodium of which five infect humans. 
Plasmodium falciparum is the predominant species in tropical and subtropical areas 
especially in sub-Saharan Africa and is responsible for the majority of deaths due to malaria 
(White, Pukrittayakamee et al. 2014). 
P. falciparum can cause severe malaria as it quickly reproduces in the blood and cause 
anemia. Subsequently, the infected erythrocytes may coagulate in small blood vessels and 
when this happens in the brain the outcome may be deadly (CDC). P. vivax is predominant 
in South East Asia, Latin America and in some part of Africa (Autino, Noris et al. 2012). P. 
ovale is principally widespread in West Africa and the islands of western Pacific. Two distinct 
sub species of P. ovale have recently been described namely P. ovale walikeri and curtisi 
(Sutherland, Tanomsing et al. 2010). P. malariae is found worldwide but at low prevalence 
and is the only species that has three-day cycle. Most of the malaria parasite species have a 
two-day cycle. P. malariae can cause chronic infection and leads to serious complications if 
untreated. P. knowlesi is present in South East Asia particularly in Malaysia and causes 
malaria in long-tailed and pig-tailed macaques but it has also been shown to infect humans. 
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P. knowlesi has a 24-hour cycle and can rapidly progress from uncomplicated to a severe 
infection (White, Pukrittayakamee et al. 2014). 
The life cycle of malaria parasites that infect humans is complex and involves two hosts, 
human and mosquito vector. The infected female Anopheles mosquito injects sporozoites into 
the human host during a blood meal. Subsequently, motile sporozoites travel to the liver and 
infect hepatocytes. Inside the hepatocytes each sporozoite matures into schizonts and 
multiplies to produce 8-32 merozoites. Upon rupture of the hepatocytes the merozoites infect 
erythrocytes. The parasites undergo asexual multiplication in the erythrocytes (Fig. 1). 
The parasites go through several stages, starting as ring stage, developing into trophozoites 
and finally becoming mature schizonts, which then rupture the erythrocyte and release 
daughter merozoites. A small fraction of merozoites form sexual gametocytes, that is able to 
transmit from human to mosquito vector. Gametocyte maturation is measured in stages. 
Stages I-IV are referred to as immature gametocytes and are sequestered in the bone marrow. 
Only stage V mature gametocytes circulate in peripheral blood and are taken up by a feeding 
mosquito. Each gametocyte forms one female macrogamete and/or up to eight male 
microgametes (Cowman et al. 2002). 
In the mosquito mid-gut the microgamete fuses with the macrogamete, producing a zygote 
that develops into a motile ookinete. The ookinete penetrates the mid-gut wall and forms an 
oocyst, which divides and bursts to release sporozoites that migrate to the mosquito salivary 
gland. The sporozoites can be injected into a new host during a blood meal (Cowman et al. 
2002). 
The life cycle between Plasmodium species is similar, with some distinguishing differences. 
In P. vivax and P. ovale, sporozoites may not follow the same multiplication rate as in P. 
falciparum and stay dormant (hypnozoites) in the liver, causing relapse of malaria between 
two weeks to more than one year after initial infection (CDC, White, Pukrittayakamee et al. 
2014). The exoerythrocytic stage do not cause a disease and does not generate symptoms or 
signs of the disease. The pre-erythrocytic phase takes 5-7 days for P. falciparum, 6-8 days for 
P. vivax, 9 days for P. ovale and 14-16 days for P. malariae. The asexual replication cycle in 
the erythrocytes takes 48 hours for P. falciparum and P. vivax, 50 hours for P. ovale and 72 
hours for P. malariae (Bousema, Okell et al. 2014). 
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Fig. 1. The life cycle of P. falciparum. Plasmodium parasites life cycle involves two hosts, 
the mosquito vector (left) and the human hosts (right). Malaria infection starts with the 
transmission of Plasmodium parasites from a female Anopheles mosquito vector and to 
human host. Approximate number of parasites in each host at each stage (1=~104-105 
(Merozoites), 2=~1010-1012 (ring stage), 3=~108-1010 (gametogenesis), 4=~102-104 (female 
& male gametes), 5=~1-10 (Oocyst), 6=~104-105) (sporozoites in mosquito) and 7=~1-102 
(sporozoites in human host) are shown to emphasize the enormous expansion that occur 
during the parasite life cycle. In the mosquito, during the sporogony process in an oocyst, 
Plasmodium parasites undergo several rounds of DNA replication (meiotic and mitotic 
replication) to produce thousands of haploid sporozoites that infect human host. In the human 
host, parasite DNA replication occurs in hepatic schizogony, erythrocytic schizogony and 
gametogenesis. Plasmodium parasites DNA replication is asynchronous and can generate an 
array of sister chromatids up to ~24n. Illustration by Madle Sirel. 
This thesis will focus on the deadliest form of the malaria parasite, P. falciparum, which is 
responsible for the vast majority of the morbidity and death especially among children 
under the age of five. P. falciparum is also most closely associated with drug resistance and 
hence responsible for the majority of the global malaria burden. 
 
1.3 PATHOGENESIS OF PLASMODIUM FALCIPARUM MALARIA 
The pathogenesis of P. falciparum infection is a multifaceted interaction of parasite-induced 
erythrocyte alterations and microcirculatory abnormalities. Clinical manifestations of P. 
falciparum infection are generated by the asexual erythrocytic of blood stage parasites. 
During the asexual and sexual intraerythrocytic development of P. falciparum, numerous 
molecular processes cause the alteration of uninfected and infected erythrocytes, but how 
these alterations become pathogenic is not completely understood. Splenomegaly is a 
common feature of endemicity in P. falciparum transmission areas and it correlates with a 
decrease hemoglobin level (Snow et al. 1997). Patients who died from severe malaria have 
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larger spleens than patients who died from sepsis (Urban et al. 2005). However, splenic 
rupture due to malarial splenomegaly is uncommon (Imbert et al 2010). In uncomplicated 
malaria patients with splenomegaly, the clearance of heat-stiffened autologous red blood cells 
(RBCs) was increased before antimalarial drug treatment (White et al. 2017, Looareesuwan 
et al. 1987). The destruction of labeled autologous RBCs was markedly increased in patients 
with severe malaria. Other malaria infection symptoms are severe anemia due to recurrent 
infections, premature delivery or delivery of a low-birth-weight infant during pregnancy, 
neurologic defects such as ataxia, palsies, blindness, deafness and speech difficulties, which 
may sometimes persist especially in children who have cerebral malaria (cdc.gov). 
1.3.1 Uncomplicated malaria 
 
Malaria disease can be classified as uncomplicated and complicated malaria. Uncomplicated 
malaria can be caused by all Plasmodium species and patients have circulating parasites but 
no severe symptoms. Generally, symptoms arise 7-10 days after initial mosquito bite. Clinical 
manifestation of uncomplicated malaria includes sensation of cold, shivering, fever, 
headaches, nausea, vomiting, seizures in young children, sweating and general malaise. 
Diagnosis of malaria depends on the confirmation of parasites in the erythrocyte, typically by 
microscopy. Other laboratory finding might include mild decrease in blood platelets, bilirubin 
elevation, mild anemia and aminotransferases elevation (CDC.gov., Mawson et al. 2013). 
1.3.2 Severe malaria 
 
Clinical manifestations of severe P. falciparum infections depend on the nature and severity 
and differential diagnosis from other conditions. Severe malaria is often linked to 
hyperparasitemia and is associated with increased mortality. Clinical manifestations of severe 
malaria include cerebral malaria, severe anemia and hemoglobinuria due to hemolysis, acute 
respiratory distress syndrome, abnormalities in blood coagulation, acute kidney injury, 
cardiovascular collapse, hyperparasitemia, metabolic acidosis, and hypoglycemia (low blood 
glucose). Cerebral malaria is a medical emergency that demands urgent treatment. 
Pathogenesis of cerebral malaria is caused by vascular endothelium damage through parasite 
sequestration, generation of inflammatory cytokine and vascular leakage, which results in 
brain hypoxia (Beeson et al. 2002, Yusuf et al. 2017). In children who have cerebral malaria, 
neurologic defects such as ataxia, palsies, blindness, deafness, and speech difficulties may 
sometimes persist. Patients with impaired immunity including pregnant women and HIV 
positive patients are most susceptible to severe malaria. However, if these patients with 
impaired immunity survive the repeated infections, more or less semi-immunity to malaria is 
developed over the years. Such immunity can neutralize the parasites through various 
mechanisms. Severe malaria should be treated quickly and aggressively, if left untreated the 
outcome can be fatal (Beeson et al. 2002, Buffet et al. 2011, cdc). 
 
1.4 MALARIA TREATMENT – ANTIMALARIAL DRUGS 
Generally, malaria is a curable and preventable disease if diagnosed early and treated properly 
and promptly with effective antimalarial drugs. The length of treatment and types of drugs 
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vary, depending on the species of malaria parasite involved and severity of the disease. There 
are three major classes of antimalarial drugs: quinolines, folate antagonists and artemisinin 
compounds. Quinoline, quinine, mefloquine and artemisinin are effective antimalarial drugs, 
however, there is a serious concern that P. falciparum has developed resistance to almost all 
antimalarial drugs. There is growing pressure in maintaining the efficacy of current treatments 
and developing alternative treatments. Several approaches have been evaluated to overcome 
drug resistance, including combination therapy which involves the combination of two or 
more antimalarial drugs and hybridization approach which involves the combination of two 
distinctive pharmacophoric features from known and new antimalarial drugs to create a 
compound with increased efficacy against most parasite stages (Capela et al. 2011, Murugan 
et al. 2015, Rajendran et al. 2015, Fivelman et al. 2007). Hybrid approach is more effective 
compared to the combination therapy because of the lower occurrence of adverse drug 
reactions (ADRs) induced by drug-drug interactions (DDIs). Antimalarial drugs studied in 
this thesis are presented in Figure 2. In the first part of this thesis, we apply the tools of whole 
genome sequencing to study the factors contributing to the acquisition of drug resistance in 
P. falciparum. 
 
1.4.1 Amodiaquine (AQ), Chloroquine (CQ) and Piperaquine (PPQ) 
 
The importance of antimalarial drugs with the 4-aminoquinoline scaffold including AQ and 
CQ has inspired research centers and pharmaceutical companies to focus on designing and 
synthesizing new analogues of these quinoline-based antimalarial drugs (Parhizgar et al. 
2017). AQ and CQ are 4-aminoquinoline derivatives and widely used as antimalarial drugs. 
AQ, CQ and other quinoline analogues are fast-acting and highly effective blood 
schizonticidal drugs against P. falciparum. AQ has been associated with severe cases of acute 
hepatitis and agranulocytosis which can be deadly. It has been used extensively to treat and 
prevent malaria since the 1940s. Although AQ is effective against CQ-resistant P. falciparum 
strains, its usage has been restricted due to hepatic and hematological toxicities (Parhizgar et 
al. 2017). 
Like other quinoline compounds, AQ mechanism of action has not been fully studied, AQ 
seems to inhibit heme polymerase activity in the body, resulting in accumulation of free heme 
which is toxic to the malaria parasites (Hasugian et al. 2009). AQ is used in combination with 
artesunate for the treatment of infection by CQ resistant P. falciparum (Adjuik et al. 2002). 
CQ-resistant P. falciparum first developed in the late 1950s and 1960s in Southeast Asia, 
South America and Oceania (Jensen et al. 2009). The spread of malaria parasites resistant to 
CQ and their cross-resistance to other analogues have decreased their usage in many malaria 
endemic areas. Although CQ is more effective and safer than quinine as a blood schizonticidal 
drug, it is not active against the liver stage and mature gametocytes (Parhizgar et al. 2017). 
PPQ is a dimer of CQ analogue and was widely used for the treatment of CQ-resistant P. 
falciparum strains in China (Wells et al. 2010, Davis et al. 2005). PPQ consists of two 4- 
aminoquinoline groups which have been coupled to each other by dipiperazine-propyl linker 
(Parhizgar et a. 2017). PPQ activity against the resistant P. falciparum parasites is attributed 
to its bulky structure that inhibits its connection to the PfCRT (CQ resistance transporter) site. 
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It is known that PPQ is trapped in the food vacuole of the parasite with its positive charges 
and inhibits detoxification of heme in the malaria parasites. The pharmacokinetic properties 
of PPQ show high lipid-solubility, tolerability, good bioavailability, fast clearance and long 
elimination half-life. Recently, the occurrence P. falciparum resistance to PPQ has reduced 
monotherapy usage (Hung et al. 2004). 
1.4.2 Artemisinin (ART), Artesunate (ATS) and Dihydroartemisinin (DHA) 
 
ART and its derivatives are very important class of antimalarial drugs. ART or qinghaosu is 
a sesquiterpene lactone and is a natural compound originated from Chinese herb qinghao or 
Artemisia annua (Sweet wormwood) (Hyde et al. 2007, Tu et al. 2016). ART is effective 
against multi-resistant P. falciparum and has broad stage specificity throughout the asexual 
blood stages (Price et al. 1996, ter Kuile et al. 1993). ART has also been used to treat fever 
and hemorrhoids (Ciu et al. 2009, Maude et al. 2010) and recent studies have shown that ART 
and its derivatives can potentially inhibit the growth and proliferation of cancer cells (Konstat- 
Korzenny et l. 2018, Hou et al. 2008, Lai et al. 2013). ATS, dihydroartemisinin and artemether 
are the most important ART derivatives and show better efficacy, tolerability, minimal side 
effects and oral bioavailability than ART due to poor solubility of ART (Chen et al. 1994, 
Meshnick et al. 2002). ATS is the most effective ART derivative compound that can reduce 
parasitemia rapidly in a single 48-h erythrocytic cycle (Chen et al. 1994) and in animal 
experiments ATS showed anti-allergic properties by effecting mast cell degranulation which 
makes ATS a promising candidate for allergic asthma treatment (Cheng et al. 2013, Cheng et 
al. 2011). Although there are less data on DHA, but studies suggested that DHA showed rapid 
parasite clearance with single high-dose regimens (Djimde et al. 2009, Guo et al. 2018). 
ART and its derivatives are known to act rapidly but are also eliminated rapidly. Their rapid 
action makes these drugs especially effective against severe malaria. Their rapid clearance 
could be an important factor why resistance to ART has been slow to develop, and may also 
explain why failures in treatment are so common when these drugs are used in monotherapy 
(Meshnick et al. 2002). It has been recommended that ART and its derivatives should not be 
used as oral monotherapies for uncomplicated malaria treatment due to poor adherence to the 
required 7 days of treatment, which results in partial parasite clearance that can promote 
resistance to this important class of antimalarial drugs (Castelli et al. 2012, Eastman et al. 
2009, Tilley et al. 2016). The emergence of antimalarial drug resistance has led to an 
augmentation of efficiency monitoring to permit early detection of resistance. In 2015, 
malaria control programs are implementing ACTs (artemisinin-combination therapies) as 
standard treatment for P. falciparum malaria worldwide (WHO, 2015). 
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Chloroquine, C18H26ClN3 Amodiaquine, C20H22ClN30 
 
 
Piperaquine, C29H32Cl2N6 Artesunate, C19H28O8 
 
 
Dihydroartemisinin, C15H24O5 Artemisinin, C15H22O5 
Fig. 2. Molecular structures of AQ, ART, ATS, DHA AND DHA. 
1.5 RESISTANCE TO ANTIMALARIAL DRUGS 
Antimalarial drugs such as quinine, CQ and its analogues compounds, ART and its 
derivatives have been used to treat and prevent malaria. Although the use of these antimalarial 
drugs has long history, the occurrence of resistance to these antimalarial drugs is a somewhat 
new phenomenon. Resistance to antimalarial drug is defined as the capability of malaria 
parasites to survive and/or multiply regardless of the administration and absorption of a drug 
given in doses at least equal to those recommended, but within the tolerance limits of the 
subject (WHO, 1986). In an effort to fight resistant strains, a number of alternative synthetic 
antimalarial drugs were implemented to both treat and prevent malaria (Packard et al. 2014, 
Ashley et al. 2018, Flannery et al. 2013). The drawbacks of the new therapies were their 
increased cost, which made them less available to the populations at the highest risk. To 
prevent the development of resistance to artemisinin-based drugs, the World Health 
Organization (WHO) recommended the usage of ACTs. The combination of artemether along 
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with lumefantrine (long-acting antibiotic) proved to be 97% effective in curing the deadliest 
forms of P. falciparum malaria. WHO initially restricted the usage of these products to the 
treatment of complicated P. falciparum malaria due to the fear that wider use would 
contribute to drug resistance, but in 2010 the WHO reversed its policy due to the pressure 
from national health programs and consequently ACTs have become the first-line treatment 
for P. falciparum malaria in many endemic countries (Packard et al. 2014). However, the 
WHO’s fear that the widespread use of ACTs would accelerate the resistance development is 
not unjustified. It has been reported that resistance to artemisinin-based drugs has occurred in 
several locations in Southeast Asia (Ashley et al. 2014). There is a tendency to view 
antimalarial drug resistance development as an unavoidable outcome of the drugs´ extensive 
use (White et al. 2004). Nevertheless, resistance to antimalarial drugs has been accelerated by 
the way the drugs are used and also by the economic and social circumstances in which they 
are used (Packard et al. 2014). It has been reported that mass drug-administration (MDA) 
programs may have also contributed to the increase of drug resistance and there is a strong 
connection between the geographic areas where MDA programs were implemented and the 
places where drug resistance developed (Packard et al 2014). It has been suggested that the 
emergence of artemisinin resistance is due to malaria parasites prone to mutation (Dondorp 
et al. 2010). Furthermore, an intensive campaign to eliminate ART resistance in the greater 
Mekong Delta region and prevent further spread of ART resistance focuses on identifying 
and treating to cure all cases of malaria in the region. Whether these efforts will be successful 
remain uncertain. In order to prevent ART-based drugs from following CQ path, efforts to 
address the social and economic circumstances that contribute to the spread of resistance to 
antimalarial drugs such as the marketing of monotherapies and cheap counterfeit drugs 
containing subclinical quantities of artemisinin are crucial. It is also important that 
investments continue to flow in the development and production of new antimalarial drugs. 
 
1.5.1 Antimalarial drugs mode of action and resistance mechanism 
Malaria parasite inherent resistance is one constituent that defines the efficacy of antimalarial 
drug in vivo. Antimalarial pharmacological properties and human immune responses play 
crucial roles in determining the clinical outcome of antimalarial drugs treatment. 
CQ acts by interfering with the detoxification of hematin, a toxic byproduct of hemoglobin 
degradation, in the food vacuole of P. falciparum. Although CQ is no longer recommended 
for the treatment of P. falciparum parasites, it is still the drug of choice for the treatment of 
P. vivax and P. ovale, less severe forms of malaria which can cause recurrent infections 
(Travassos & Laufer 2010). 
AQ plasmodial action is not completely clear. Like other quinoline analogues, it is thought 
to inhibit heme polymerase activity, which results in free heme accumulation that is toxic to 
the parasites. AQ binds to the free heme and prevent the malaria parasite from converting 
heme to an inactive form. AQ-heme complex disrupts membrane function (Jewell et al. 1995, 
Harrison et al. 1992). PPQ mechanism of action is expected to be quite similar to that of CQ 
(Davis et al. 2005) 
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ART and DHA mechanism of action has not been fully studied, but they may act via a 
common mechanism (White et al. 1994). ART and DHA are believed to bind to heme within 
the P. falciparum parasites and the source of this heme may vary with the intraerythrocytic 
developmental stage of the parasites (Wang et al. 2015, Paitayatat et al. 1997). In early ring 
stage ART and DHA are thought to bind to heme produced by the parasite´s heme 
biosynthesis pathway and in the later stages they possibly bind to heme release by hemoglobin 
digestion (Olliaro et al. 2001). When bound to heme, ART and DHA are believed to undergo 
activation involving ferrous iron via reductive scission that splits the endoperoxide bridge to 
produce a reactive oxygen species (ROS) (Olliaro et al. 2001, Haynes et al 1996). This 
reactive oxygen is believed to undergo a subsequent intramolecular hydrogen abstraction to 
produce reactive carbon radical which is thought to be the source of the drugs potent activity 
against P. falciparum by alkylating a wide range of proteins targets (Olliaro et al. 2001, 
Ravindra et al. 2015, Wang et al 2015). The degree to which this alkylation affects specific 
protein function is still not known. Proteomics studies show that ART and its derivatives 
alkylate hundreds of proteins, suggesting that the drugs may kill the parasite by inducing 
global degradation of its cytoplasm (Wang et al. 2015, Ismail et al. 2016). Other studies 
suggested that ART inhibits the sacro/endoplasmic reticulum Ca2+ ATPase found in 
Plasmodium parasites (Asawamahasakda et al. 1994, Eckstein-Ludwig et al. 2003). ART and 
DHA appear to specially accumulate in the infected red blood cells, where drug 
concentrations are higher by several hundred folds compared to uninfected red blood cells 
(Gu et al. 1984). ATS mechanism of action is believed to involve cleavage of the 
endoperoxide bond via reaction with heme (Artesunate product Information). 
This generates free radicals that alkylate parasitic proteins. ATS has been demonstrated to 
inhibit an important parasite calcium adenosine triphosphate enzyme. ATS is thought to 
inhibit malaria protein EXP1, a glutathione S-transferase, and accounting for the breakdown 
of cytotoxic hematin (Lisewski et al. 2014), but it is still not clear to what extent this inhibition 
contributes to the antimalarial action of ATS. 
The occurrence of resistance in Plasmodium is determined by several factors such as parasite 
mutation rate, the fitness costs correlated with the resistance mutations, total parasite load, 
the strength of selection of drug and the compliance of treatment (Petersen et al. 2011). The 
rate of mutation in the parasites has a direct effect on the frequency at which resistance can 
occur. Though higher rates of mutations allow for a faster occurrence of resistance, they may 
also lead to an accumulation of harmful mutations (Petersen et al. 2011). The mutation rate 
in P. falciparum was determined to be approximately 10-9 from experiments measuring 
spontaneous mutations in the Pfdhfr (P. falciparum dihydrofolate reductase) gene, which is 
quite low (Paget-McNicol et al. 2001). An increased rate of mutation is beneficial for the 
parasite’s adaptation to quickly changing environments (Sniegowski et al. 2000). Some 
studies reported an accelerated resistance to multiple drugs (ARMD) phenotype present in 
parasite isolates from Southeast Asia. In vitro experiments showed that parasites with the 
ARMD phenotype developed resistance to drugs at a higher rate than other geographically 
distinct parasite strains, and such ARMD parasites might explain the observation that 
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resistance to new antimalarial drugs often occurs first in Southeast Asia (Rathod et al. 1997). 
Transmission is additional crucial step for the spread of antimalarial drug resistant parasites 
and the intensity of transmission has a significant role in the determining if parasites are 
efficiently spread during a mosquito blood meal (Petersen et al. 2011). Moreover, antimalarial 
drug resistance may increase transmission if drug selection pressure reduces the viability of 
sensitive gametocytes in a multiple-strain infection, enhancing the tendency for transmitting 
antimalarial drug-resistant parasites (Hastings et al. 2006). 
Since mutations are associated with drug resistance, several studies have identified the cause 
of resistance by sequencing of full P. falciparum genome, which revealed approximately 
5300 genes distributed among 14 chromosomes (Gardner et al. 2002). P. falciparum parasite 
could alter its response to drug through regulation of gene expression. Most mutations in 
relation to antimalarial drug resistance are either single nucleotide polymorphisms (SNPs) in 
the regulatory areas surrounding the genes, which could change the gene expression, 
insertion/deletion in a coding area of gene that might alter protein structure and functions, or 
gene amplifications (Gardner et al. 2002). 
The mechanism of resistance to CQ is thought to be associated with polymorphisms in PfCRT 
(P. falciparum chloroquine resistance transporter) (Sidhu et al. 2002). PfMDR1 (P. 
falciparum multidrug resistance 1) also modulates the degree of CQ resistance in some 
parasite strains, signifying that some alleles and overexpression of PfMDR1 can enhance the 
CQ concentration in the food vacuole by active transport (Barnes et al. 1992). Remarkably, 
studies have showed linkage disequilibrium between PfCRT and PfMDR1 alleles in CQ 
resistant parasites in Southeast Asia and Africa, signifying a functional interaction between 
these proteins (Menard and Dondorp et al. 2017, Osman et al. 2007). Cross-resistance 
between AQ and CQ has been described and mutations in PfCRT and PfMDR1 are linked 
with reduced susceptibility to both AQ and CQ, but this cross-resistance is inadequate since 
some CQ resistant parasites remain susceptible to AQ (Sá et al. 2009). It has been established 
that modulation of PPQ susceptibility by mutations in PfCRT, however the alteration in PPQ 
response was unclear and clinical significance of this discovery remains uncertain 
(Muangnoicharoen et al. 2009). 
Resistance to ART and its derivatives is seen in the ring stage of parasites that show delayed 
clearance from circulation after direct administration of ARTs to patients (Noedl et al. 2008, 
Dondorp e al. 2009, Witkowski et al. 2013). Pfkelch13 gene in parasites is the main marker 
of ART resistance as demonstrated both clinically and in in vitro studies using the ring stage 
survival assay (Witskowski et al. 2013). Mutations in Pfatp6 (P. falciparum Ca2+ 
transporting ATPase 6) has been linked to decreased artemether sensitivity in field parasite 
isolates from French Guyana (Jambou et al. 2005) and polymorphisms in ubp1 (encoding for 
deubiquitination enzyme) are linked to increased resistance to ATS in the rodent P. chabaudi 
parasites (Hunt et al. 2007). However, artemether and ATS resistance does not demonstrate 
consistent association with malaria parasites with delayed clearance, the presently described 
phenotype of P. falciparum parasites with decreased ART susceptibility (Imwong et al. 2010). 
Though not mediating complete ART derivative resistance, PfMDR1 amplification may 
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considerably decrease parasite susceptibility (Sidhu et al 2006, Imwong et al. 2010, 
Chavchich et al. 2010). Global transcriptomic profiling of over a thousand clinical strains led 
to the discovery of upregulation of parasite oxidative stress and protein damage pathways via 
unfolded protein response (UPR) as a mechanism of ART resistance in parasites with 
Pfkelch13 mutations (Mok et al. 2015). 
 
1.6 PLASMODIUM FALCIPARUM GENOME 
P. falciparum 3D7 clone was the first Plasmodium genome to be sequenced (Gardner et al. 
2002). The genome consists of ~23.3-megabase (Mb) of nuclear genome distributed among 
14 linear chromosomes (with telomeres and centromeres) ranging from 0.643 to 3.29 Mb in 
size, about 6-kilobase (kb) of mitochondrial and a 35-kb circular apicoplast genome. The 
apicoplast genome encodes only 30 proteins including housekeeping enzymes involved in 
DNA replication, transcription, translation and post-translation modifications, protein export 
and turnover, cofactor synthesis and specific metabolic and transport activities. 
Approximately 60% of the apicoplast genome is of unknown function. About 60 genes are 
identified as of mitochondrial origin. Most of the proteins encoded by these mitochondrial 
genes have known functions such as tricarboxylic acid (TCA), oxidative damage protection, 
synthesis of heam, and ubiquinone. 
The P. falciparum genome is extremely AT-rich (~80%), and increases to ~90% in non- 
coding regions. The genome encodes approximately 5300 genes. The average gene density is 
1 gene per 4,338 base pairs (bp) and the average length was 2.3 kb without introns. 15.5% of 
genes are more than 4 kb in length which is much longer compared to other organisms. Many 
of these large genes encode proteins of unknown function. Notably, P. falciparum genome 
encodes a small proportion of enzymes and transport proteins and a large proportion of genes 
that are involved in immune evasion and host-parasite interactions. Genes involved in 
antigenic variation (e.g. var, rif and stevor) are located in the subtelomeric regions of the 
chromosomes. 
Plasmodium also encodes DNA replicative machinery such as DNA polymerases (Gardner 
et al. 2002), proliferating cell nuclear antigen (PCNA) (White et al. 1996, Mitra et al. 2015, 
Kilbey et al. 1993), and minichromosomes maintenance proteins (MCMs) (Ansari et al. 
2012). P. falciparum genome also encodes at least some major components of DNA repair 
processes that are also found in other eukaryotes including genes involved in nucleotide 
excision repair (RAD25, RAD2, RAD1, RAD3 and ERCC1) and homologous recombination 
repair (MRE11, RAD50, RAD51, RAD54 and DMC1), although some of the accessory 
proteins such as XRS2, RAD4, XPC that are found in eukaryotes have not yet been found in 
P. falciparum. Other genes involved in DNA repair processes that are also found in 
eukaryotes are genes involved in post-replication mismatch repair (MSH6, MLH1, MSH2-1, 
MSH2-2 and PMS1) and base excision repair (glycosylase homologues and 
apurinic/apyrimidinic (AP) endonucleases). Interestingly, homologues of the genes encoding 
enzymes involved in non-homologous end joining (NHEJ) repair in eukaryotes such as Ku70, 
Ku86, Ligase IV and XRCC1 are apparently absent in P. falciparum. NHEJ repair genes are 
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important in repairing DNA double strand breaks (DSBs) and other cellular processes that 
create DSBs. In other organisms, NHEJ plays an important role in regulating telomere 
stability (Eisen et al. 1999, Dudásová et al. 2004). 
 
1.7 DNA DAMAGE AND REPAIR 
Plasmodium falciparum DNA is subjected to damage from immune response, DNA 
damaging agents such as reactive oxygen species produced by the parasite’s metabolic 
processes, free radicals generated after uptake of antimalarial drugs including ART, ATS or 
CQ, genotoxic agents and DNA replication errors when it reproduce asexually within 
mammalian host (Berdelle et al. 2011, Li et al. 2008). This damage may affect individual 
bases or may lead to the production of DSBs. DNA damage together with damage in the 
protein is believed to be a mode of action for ART, mediated via free radicals (Gopalakrishnan 
et al. 2015). Plasmodium parasites enter dormancy at G0/G1 phase and upregulate DNA 
repair machinery particularly PfRAD51, PfRAD54, PfRPAIl and PfRPAIS in response to 
ART (Gupta et al. 2016, Gopalakrishnan et al. 2013). This dormancy may be a key  
mechanism of ART resistance. 
DNA damage from transcription, collapse of replication fork or by-product of cellular 
processes including hemoglobin degradation, has not been well studied in P. falciparum. 
However, it has been reported that when parasites grow in the RBCs, they degrade 
hemoglobin in their digestive vacuoles and release heme. This heme is oxidized from ferrous 
(Fe2+) to ferric (Fe3+) iron which leads to the generation of hydroxyl radicals, a powerful DNA 
damaging agent (Atamna et al. 1993). Thus, it is feasible that in P. falciparum parasites, 
cellular processes including degradation of hemoglobin in the digestive vacuole and the 
release of free radicals, together with the many rounds of DNA replication may lead to DSBs, 
which need to be repaired in order to maintain DNA integrity that is crucial to genomic 
stability and parasite viability. 
Like all other pathogens, malaria parasites must rely on DNA repair mechanism to correct 
damaged nucleotides. DNA damage repair is a process by which a cell identifies and corrects 
damage to the DNA molecule. DNA damage repair is closely tied to DNA replication to 
ensure precise copying of the genome. DNA damage may lead to multiple lesions such as 
deletions, insertions, mutations, translocations, and loss of chromosomes and genetic 
information. In the Plasmodium genome, DNA repair machinery is largely conserved, and 
parasites respond to DNA damage by upregulation of the DNA repair machinery and 
alteration of chromosome structure (Gupta et al. 2016). 
In mammalian cells, the signaling system of DNA damage is complex and involves proteins 
that can be classified into four groups: sensors, transducers, mediators and effectors. DNA 
damage response mechanism includes DNA damage detection, multiple DNA repair 
pathways, damage tolerance processes and cell-cycle checkpoints to maintain genomic 
integrity (Gaglia-Mari 2011). In Plasmodium, the existence of cell cycle checkpoints remains 
unclear and genes encoding checkpoint proteins such as ATM, ATR and p53 have not yet 
identified (Matthews et al. 2018). 
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DNA damage response is a chromatin-associated process that is usually closely controlled in 
time and space (Giglia-Mari et al 2001). In eukaryotes, chromatin plays a crucial role in 
regulating the DNA damage response. Histone modification and chromatin remodeling 
complexes alter the chromatin structure to give access to the damage site for the DNA repair 
genes during DNA damage. Phosphorylation of H2A/H2A-X and acetylation of H4 play vital 
roles in the recruitment DNA repair genes includes ATM and ATR kinase, RAD51, BRCA1, 
TIP60 HAT, TP53. In P. falciparum RAD51 performs homologous recombination repair to 
change the expression of genes encoding surface membrane glycoproteins and create 
antigenic variation (Freitas-Junior et al. 2000). In addition, recombinational rearrangements 
are accountable for the multidrug resistance gene (pfmdr1) amplification (Triglia et al. 1991) 
indicating the importance of homologous recombination repair to create genomic adaptability 
and plasticity in Plasmodium parasites. The majority of histone modifications and chromatin 
remodeling complexes have been identified in P. falciparum but the role of chromatin 
dynamics in the DNA response is still to be explored. Recent studies have showed that 
chromatin structure is altered during DNA repair (Gupta et al. 2016). 
DSBs are one of the most severe types of DNA damage as they affect both strands of DNA 
and lead to loss of genetic information. DBS has been extensively studied in Saccharomyces 
cerevisiae (Paques and Haber 1999, Krogh and Symington 2004). DSBs have to be repaired 
to prevent chromosomal rearrangements and accumulation of further mutations (Lee et al. 
2014). 
Other DNA lesions consist of single-strand breaks, inter- and intra-strand crosslinks, adjacent 
nucleotides crosslinking and base modifications, base mismatches during replication as well 
as non-bulky lesion produced by alkylation, deamination, and oxidation of bases. After DNA 
is damaged, sensors such as MRN/X (Mre11/Rad50/NBS1 (XRS2) and Ku70/Ku80) bind to 
damaged sites and recruit transducers that help amplify and maintain the DNA damage signal. 
These sensors play a vital role in DNA double-strand breaks repair. In addition, transducers 
such as Ataxia telangiectasia mutated (ATM), DNA-PKcs are key factors involved in several 
pathways in the DNA damage response. The interaction between the transducers and the 
mediator proteins leads to the signal dispersal all over the cell nucleus and effectors kinases 
are activated. (Hoeijmakers et al. 2009). 
The variety of mutations observed in P. falciparum is highly uncommon. SNP mutation rate 
is approximately 2.45x10-10 mutations per base pair per life cycle (Matthews et al. 2018), due 
to the presence of effective DNA repair system. Recent studies have shown that parasites 
respond to DNA damage through upregulation of specific DNA repair genes and at the same 
time alter its chromatin structure (Gupta et al. 2016). Studies from Cambodian isolates 
identified mutations in a number of DNA repair genes, including MLH1, PMS1 and EXO1 
in MMR pathway (Lee et al. 2014). It has been proposed that accelerated resistance to 
multiple drugs (ARMD) parasites have reduced DNA repair efficiency as compared to non- 
ARMD parasites, which may trigger their increase mutational features. Furthermore, whole 
genome sequencing identified point mutations of 18 DNA repair genes, which is believed to 
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contribute to the ARMD phenotype, due inefficient repair in the DNA damage (Gupta et al. 
2016). 
 
1.8 DNA REPAIR PATHWAYS 
DNA repair pathways function to defend against genomic damage imposed by various 
sources, including host immune response, replication errors, and metabolic byproducts. P. 
falciparum has a complex life cycle and probably needs refined global and local regulators, 
including refined DNA repair mechanisms and checkpoint, however these are currently not 
fully understood. Other infectious organisms including bacteria may possibly profit from 
mistakes in DNA repair, as such errors usually cause variation that can contribute to the 
development of drug resistance or other means of accelerated adaptation to the host (Sinha et 
al. 2007). 
DNA repair can be divided into six pathways: homologous recombination repair (HRR), non- 
homologous end-joining (NHEJ), base excision repair (BER), nucleotide excision repair 
(NER), mismatch repair (MMR), mitotic recombination and methyltransferase repair. 
Homologous recombination (HR) and canonical nonhomologous end joining (C-NHEJ) are 
the two well-characterized mechanisms for DNA DSB repair in both eukaryotes and 
prokaryotes (Moynahan and Jasin 2010). 
HR-based repair is considered to be an error free repair and uses a template to guide repair 
while CNHEJ repair is more likely to introduce mutations. HRR pathway is a slow repair 
process and can only take place in late S phase and G2 phase, when DNA has been replicated 
and the sister chromatid is available as undamaged template, promoting high fidelity repair 
of DSBs. It involves strand resection and invasion of DNA followed by synthesis and ligation 
of DNA. After the DNA damage, the sensors (MRN/X complex) bind to DNA ends, activate 
the transducers, recruit nucleases and are involved in the end-trimming process (Shibata et 
al. 2011, Fleck and Nielsen et al. 2004). The P. falciparum genome encodes a functional 
homologous recombination pathway (Gardner et al. 2002). HRR pathway plays an important 
role for the completion of the parasite life-cycle (Fox et al 2009) and homologous 
recombination is the main source of DSB repair in the parasites (Kirkman et al. 2019, Lee et 
al. 2014). 
NHEJ repair pathway does not require a template and is available throughout the entire cell 
cycle. Compare to HR, NHEJ is a fast but error prone repair process. During DNA end 
processing, loss or changes of a few nucleotides may occur. The heterodimer Ku70/Ku80 
binds to the DNA ends at the site of DNA DSB and recruits’ transducers, which tether the 
loose ends and form a bridge. Subsequently, the DNA ends are trimmed by Artemis nuclease 
and MRN/X protein complex. Damaged bases are removed to prepare for synthesis and then 
ligation is carried out by the LigIV/XRCC4 complex (Weterings and van Gent 2004, van 
Gent and van der Burg 2007). In Plasmodium the core genes of the NHEJ pathway appear to 
be missing across the genus (Aravind et al. 2003). 
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Damage to individual bases is repaired by excision repair pathways, such as base excision 
repair (BER) in which the damaged bases are removed by DNA glycosylase and replaced 
with the correct nucleotide by DNA polymerase b in a localized burst of DNA synthesis, 
nucleotide excision repair (NER) and mismatch repair (MMR) (Matthews et al. 2018). Single 
strand breaks are usually repaired by BER mechanism (Hegde et al. 2008) (Almeida and 
Sobol 2007). P. falciparum lacks orthologs for short-patch BER, however homologs for a 
long-patch BER pathway are present (Haltiwanger et al. 2000).NER differs BER in that NER 
uses different enzymes such as Transcription Factor IIH and removes a large spectrum of 
single strand lesions that cause local helix destabilization. NER is a multi-step process and 
involves at least 25 different polypeptides and consists of two different damage detection 
modes. Transcription-coupled NER senses the damage by RNA polymerase, removes 
transcription-stalling lesions and quickly permits resumption of transcription. Global genome 
NER localizes lesions anywhere in the genome (Hoeijmakers 2009) (Gillet and Scharer 2006, 
Krokan, et al. 1997, Prakash and Prakash 2000). Bioinformatically, the orthologs of the 
majority of genes involved in the excision repair pathways in Plasmodium have been 
identified except for p62 and XPC (Tajedin et al. 2015). 
Mismatch repair mechanism corrects base-base mismatches and generates insertion and 
deletion loops during DNA replication and recombination. It is an immediate post replicative 
correction mechanism and the proteins involved are up-regulated during cell cycle. MSH2 
and MLH1 proteins are key factors in MMR and were reported to be up-regulated when 
quiescent cells were stimulated to proliferate. DNA polymerases, Exo1, PCNA and RFC are 
replication factors, which are also required in MMR. (Marti et al. 2002). Orthologs of the 
majority of the MMR pathway are present in Plasmodium however there are prominent 
differences from other eukaryotes. 
Throughout all haploid growth phases, Plasmodium parasites must depend upon alternative 
end joining pathways such as microhomology-mediated end joining (MMEJ) to repair DSBs 
in the core genome, because there is no repair template to allow for HR repair (Singer et al. 
2015). MMEJ repair is inefficient or used infrequently and that Plasmodium parasites with 
1N genome content are incapable to repair DNA damage as efficiently as trophozoites with 
2N or more genome content (Oakley et al. 2013, Waki et al. 1983, Waki et al. 1985). In 
eukaryotes, MMEJ involves initial sensing and resection of double-strand break. DSB is first 
sensed by the sensor MRN/X complex (Mre11-Rad50-NBS1/Xrs2), which then binds to the 
double stranded ends, positions both ends in close proximity and initiates 5' - to 3' resection 
together with Sae2, creating short 3' terminated single-stranded DNA (ssDNA) tails. This is 
followed by 5'-to 3' extensive resection by redundant factors such as Exo1 (exonuclease 1), 
Sgs1, Top3, Rm1 and Dna2 complex that commits DSBR to HR and produces long 3' ssDNA 
tails (Lee, Symington et al. 2014). Alternative non-homologous end-joining (A-NHEJ) 
pathway is a backup repair pathway for abrogated NHEJ and HR repair pathways. The DNA 
repair proteins that are involved in A-NHEJ include PARP1, WRN, Mre11, CtIP, Polymerase 
d, Histone1, Lig3 and XRCC1 or Lig1 (Iliakis, et al. 2015). 
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1.9 EXTRACELLULAR VESICLES (EVS) 
In the last decade, the discovery of extracellular vesicles (EVs) as cellular communicators 
and potential biomarkers has led to an unexpected growth of publications in the field of EV 
research. The first experimental visual evidence of EVs was published by Peter Wolf in 1967 
using electron microscopy (EM) and was called platelet dust (Wolf et al. 1967). A couple of 
years later, other studies illustrated the release of submicron vesicles via a direct blebbing of 
particles of the plasma membrane from activated platelets using EM (Webber and Johnson 
1970). In later years, other work helped to define the role of vesicles in the secretory pathway 
of intracellular protein transport, especially in relation to the secretion of hormones, enzymes 
and neurotransmitters (Palade et al. 1975, Fries et al. 1980, Rothman et al. 2002). 
These studies provided significant evidence for vesicles’ role in the transfer of cellular 
substances, vesicles fusion with the plasma membrane and discharge of intravesicular 
components into the extracellular space (Rothman et al. 2002). Intercellular communication 
is important in maintaining homeostasis, tissue and organ integrity. Several types of cell-to- 
cell communication mechanisms have been investigated, such as electrical stimuli, 
extracellular matrix interactions, direct cell-cell connections and release of different 
substances. EVs such as exosomes, microvesicles, microparticles and oncosomes are a 
heterogenous collection of membrane-bound carriers with complex cargos and have emerged 
due to their role in intercellular communication that are important between cells. Like all other 
protozoans and microorganisms, malaria parasites use several pathways to communicate 
within their own populations and to influence their outside environments with the aim of 
harmonizing the growth rate and transmission (Mantel et al. 2014). 
Other pathogens such as bacteria use extracellular vesicles to export virulence effectors into 
target host cells (Kuipers et al. 2018, Szempruch et al. 2016). Cells release vesicles of 
different sizes via endosomal pathway and by budding from plasma membrane. EVs are small 
spherical vesicles, ranging from 0.1-1µm in size, which contain biomolecules including 
bioactive lipids, proteins, and genetic material such as DNA and non-coding RNA, which can 
be transferred to specific recipient cells (Jones et al. 2018, Mantel et al 2014). It has been 
suggested that EVs play an important role in cellular communication and used as biomarkers 
(Jones et al 2018). Recent studies suggest that EVs derived from pathogen or host are released 
during infection (Schorey et al. 2015). In malaria, recent evidence suggests that Plasmodium 
parasites secrete EVs to evade host immune system and to promote growth and transmission 
(Mantel et al. 2014). Cells used EVs to communicate and organize social activities and several 
types of vesicles have been identified based on their size, biogenesis and source of cellular 
compartment (Mantel et al. 2014). 
 
1.10 DIFFERENT TYPES OF EVS 
Although interests in EV research field have grown in recent years, it has been accompanied 
by a disparate use of terminology that causes misperception within the field. Researchers have 
named the vesicles based on their origin, such as oncosomes for cancer cells, tolerosomes for 
vesicles from intestinal epithelial cells and matrix vesicles for vesicles from bone cells and 
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cartilage (van der Pol et al 2015, Ostman et al. 2005, Di Vizio et al. 2009, Ronquist et al. 
2015, Schmidt et al. 2016). Other terms referring to the biogenesis mechanism including 
exosomes, microvesicles, apoptotic bodies and microparticles are often used 
indistinguishably. Hence, the International Society of Extracellular Vesicles (ISEV) 
published a paper in 2014 to encourage the use of EVs as a collective term to incorporate all 
secreted vesicles and request that authors in the EV field give complete lucidity in reporting 
the defined EV populations of study (Gould et al. 2013, Lötvall et al. 2014). Several markers 
are used to identify exosomes including annexin V (phospholipid) TSG101, heat shock 
proteins, Alix and tetraspanins such as CD9, CD63 and CD81 (Bobrie et al. 2011, Théry et 
al. 2009). Figure 4 shows the typical characteristics of EVs. 
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Fig. 4. Different types of extracellular vesicles. EV is the collective term used to comprise 
all cell-derived secretory vesicles such as exosomes, microvesicles and apoptotic bodies. 
 
1.10.1 Exosomes 
Exosome is the term often used for nano-scale subpopulations of EVs. Exosomes are 
endosome-derived membrane vesicles and are the smallest types of EVs, approximately 30- 
100nm in diameter (Bhatnagar et al. 2007, Moldovan et al. 2013). These exosomes have the 
ability to carry and deliver their cargos such as proteins, non-coding RNA and microRNA via 
direct cell-to- cell contact as well as distant signaling (Cheng et al. 2014, Mittelbrunn et al. 
2011, Moldovan et al. 2013, Ridder et al. 2014, Valadi et al. 2007). During infection, 
exosomes facilitate cell to cell information transfer and immune response regulation (Valadi 
et al. 2007). Exosomes have the capacity to be released from antigen-presenting cells to 
induce immune responses in vivo, making exosomes ideal therapeutics and biomarkers 
(Schenoda et al. 2016). Exosomes are present in cerebrospinal fluids and blood and play an 
important role in intercellular communication by transporting their cargo between source and 
target cells (Schorey et al. 2015). Several studies have suggested that exosomes might be used 
as biomarkers of infectious diseases with the potential to prevent infection. 
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1.10.2 Microvesicles (MVs) 
MVs or ectosomes or membrane vesicles are larger than exosomes, approximately 100-1000 
nm in diameter. Their release mechanism and biogenesis may differ from exosomes. MVs 
are shedded from blebbing of stressed or apoptotic cells or via fission of membrane vesicles 
from the plasma membrane which resembles the abscission step in cytokinesis (Lee et al. 
2012, Rackov et al. 2018, Stahl et al. 2018, D´Souza et al 2018, Tiberti et al. 2016). Like all 
other EVs, MVs also carry an array of inducible bioactive substances which allow their 
composition to be often augmented via induction in response to specific stimulus (Lee et al. 
2012, Rackov et al. 2018, Stahl et al. 2018, D´Souza et al 2018). The release of MVs also 
shares a common feature with the mechanism of virus budding (Jones et al. 2018). 
 
1.10.3 Apoptotic Bodies (ABs) 
ABs are another type of extracellular vesicles which are released by apoptotic cells during the 
later stages of programmed cell death as blebs. They are the largest EVs, approximately 1- 
5µm in diameter and serve as a signal stimulating phagocytosis of apoptotic cells before 
induction of necrosis (Caruso et al 2018, Christiakov et al. 2016, Rackov et al. 2018). Like 
exosomes, apoptotic bodies can also carry and transfer cargoes including oncogene, cellular 
organelles and DNA between cells, and have been shown to be crucial in presentation of 
antigen and immunosuppression (Hsu et al. 2010, Thery et al. 2001, Holmgren et al. 1999, 
Cocca et al. 2002, Bellone et al. 1997, Bergsmedh et al. 2001). Apoptotic bodies are 
augmented with different types of damage-related molecular pattern proteins, which may 
induce inflammation (Caruso et al. 2018, Christiakov et al. 2016). 
 
1.11 BIOGENESIS, COMPOSITION AND FUNCTION OF 
EXTRACELLULAR VESICLES 
The biogenesis of EVs is a highly conserved phenomenon in living organisms. The majority 
of reports on the EVs biogenesis has been elucidated in mammalian cells therefore the 
mechanisms and pathways of the generation of EVs in parasites could differ. EV generation 
pathways include the classical pathway (endocytic pathway) for the formation of exosomes 
and the direct pathway (alterations in plasma membrane asymmetry) for the formation of 
microvesicles budding. The endocytic pathway is the inward budding of plasma membrane, 
resulting in intracellular vesicles whose main function is to regulate the cell surface receptor 
expression that can be internalized and degraded or recycled depending on the cell’s needs 
(Vanlandingham et al. 2009). The direct pathway is the modifications in the asymmetry of 
the plasma membrane causing an outward budding of the membrane directly into the 
extracellular space, which leads to the production of microvesicles that contain surface 
proteins of the cell of origin (Manno et al. 2002). 
Exosomes can be found in plasma, urine, cerebrospinal fluid, saliva, amniotic fluid, 
bronchoalveolar fluid and breast milk, making exosomes the ideal candidates to serve as 
biomarkers (Corrado et al. 2013, Zhou et al. 2008). Exosome biogenesis starts after the 
formation of intraluminal vesicles as the late endosome membrane buds inward 
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(Frydrychowicz et al. 2015). The multivesicular bodies transit to the surface of the cell and 
fuse with the cell membrane and subsequently release intraluminal vesicles outside of the cell 
and into the extracellular environment (Meckes et al. 2011, Gyorgy et al. 2011). Exosomes 
are the only secreted cellular vesicles which are produced from internal membranes. Exosome 
compositions are rich in lipids and proteins, and can contain molecules involved in the 
presentation of antigens as well as numerous surface molecules that can activate different cell 
receptors and allow them to exchange materials (e.g. miRNA, carbohydrates and pathogens) 
between cells (Lee at al. 2012, Meckes et al. 2011). The recipient cell is able to take up or 
receive this cargo from the exosomes via receptor-mediated endocytosis, direct fusion with 
plasma membrane or via phagocytosis (Schorey et al. 2015). Receptor-mediated endocytosis 
comprises the direct binding of exosomes to receptors on the plasma membrane or the 
membrane of endocytic organelle of the recipient cell (Schorey et al. 2015). 
MVs biogenesis comprises vertical trafficking of different molecular cargo to the plasma 
membrane, membrane lipids redistribution and the use of contractile machinery at the surface 
allowing vesicle pinching (D'Souza-Schorey et al. 2012). MVs secreted via outward budding 
and fission of plasma membrane are the result of interplay between redistribution of 
phospholipids and cytoskeletal protein contraction (Akers et al. 2013). MV content appears 
highly enriched for protein subset. For example integrin receptors are enriched in melanoma 
cells while transferrin receptors are highly enriched in exosomes but missing in MVs 
(Muralidharan-Chari et al. 2009 & 2010). Unlike exosomes, MVs could transfer reporter 
function to recipient cells in the form of plasmid DNA (Kanada et al. 2015). 
Apoptotic bodies are formed only during apoptosis, which is a major cell death mechanism 
for both normal and cancer cells (Kerr et al. 1972, Elmore et al. 2007). Apoptotic bodies are 
characterized by the presence of organelles within the vesicles. Apoptotic body clearance by 
macrophages through phagocytosis is mediated by interactions between the phagocytes’ 
recognition receptors and the specific changes in the apoptotic cell membrane composition 
(Akers et al. 2013, Elmore et al. 2007, Taylor et l. 2008). 
EVs can be secreted by an array of cells including endothelial cells, epithelial cells, blood 
leukocytes, red blood cells (RBCs), infected RBCs (pRBCs), platelets, tumor cells, T cells, B 
cells, mast cells, astrocytes and stem cells (Corrado et al. 2013, Eldh et al. 2010, Mantel et al. 
2014, Zhou et al. 2008). EVs may contain different forms of DNA such as genomic DNA 
fragments and mtDNA (Cai et al. 2013, Waldenstrom et al. 2012, Guescini et al. 2010). EVs 
have different surface molecules and can activate several receptors that allow EVs to 
participate in the exchange of materials between cells (Lee et al. 2012). Several studies have 
shown the importance of extracellular vesicle functions as well as their unique characteristics 
such as packaging and targeting abilities (Jones et al. 2018). Numerous pathogenic organisms 
including Leishmania major, Trypanosoma cruzi, and Plasmodium species are capable of 
releasing exosomes that may play a role in the host-cell invasion and infection modulation 
(Bayer-Santos et al. 2013, Borges et al. 2016, Martin-Jaular et al. 2011, Schorey et al. 2015, 
Silverman et al. 2010). 
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1.12 THE ROLE OF EVS IN MALARIA DISEASE 
EVs have been proposed to play an important role in the transportation of molecules between 
cells for transcriptional regulation during immune and inflammatory responses and for signal 
transduction (Robbins et al. 2014, Buzas et al. 2014). It has been reported that during malaria 
infections, EVs plays an important role in disease pathogenesis and susceptibility as well as 
immune responses and cell-to-cell communication (Guimaraes Sampaio et al. 2017). Several 
studies have also shown that EV generation is elevated in different diseases including 
inflammation, cancer, and cardiovascular diseases (Kim et al. 2003, Distler et al. 2005, Jy et 
al. 1992, VanWijk et al 2003). 
In recent years, studies have indicated that circulating EVs or microparticles (MPs) were 
elevated in patients with malaria and these EVs or MPs seemed to be associated with the 
progress of immunopathological lesions in cerebral malaria (Campos et al. 2010, Combes et 
al. 2004, Nantakomol et al. 2011). Other studies found that patients infected with P. 
falciparum had the highest concentrations of RBC-derived EVs compared to heathy controls 
( Mfonkeu et al. 2010). In P. falciparum-infected patients in Cameroon, (Mfonkeu et al. 
2010) found a significant increase in circulating MVs, in particular platelet-derived EVs, in 
patients with complicated or cerebral malaria but not in uncomplicated malaria or controls. 
Furthermore, similar results were shown in a field study in India, where EVs or MVs secreted 
from endothelial cells, platelets and erythrocytes were elevated during malaria infection (Sahu 
et al. 2013). Intriguingly, an in vivo study showed that EVs from platelet bind only to pRBCs 
in a P. falciparum Erythrocyte Membrane Protein 1 (PfEMP1) dependent manner and transfer 
platelet antigens into the infected cells, but not to uninfected RBCs. These platelet-EVs 
dramatically enhance the binding of pRBCs to the endothelial cells (Faille et al. 2009). 
This study provided mechanistic understandings into the association of MVs in cerebral 
malaria, signifying that EVs can promote cerebral pathology through stimulation of iRBC 
cytoadhesion in the brain. It has also been suggested that P. falciparum EVs can mediate cell- 
to-cell communications between parasites (Mantel et al. 2013, Regev-Rudzki et al. 2013). 
Recently, a study of P. vivax infected patients in Brazil found that active infection was also 
correlated with increased MV secretion, but these MVs came from platelets, erythrocytes and 
leukocytes and not from endothelial cells (Campos et al. 2010). It has been proposed that 
these platelet-derived EVs might play an important role in the inflammatory symptoms of P. 
vivax infection (Campos et al. 2010). It is important to note that MVs were consistently found 
to be augmented with P. falciparum infection but not with P. vivax and the presence of 
endothelial derived MVs in P. falciparum infection probably reflects the main involvement 
of this type of cell in the development of cytoadherent-dependent severe malaria disease 
symptoms. EVs can induce the innate immune system from cells both in human and rodent 
malaria system and can also facilitate cellular communication between pRBCs through 
transfer of signaling molecules from donor to a recipient iRBC (Mantel et al 2013, Couper et 
al. 2010). Furthermore, this pathway of communication is associated with the development 
of malaria transmission stages (gametocytes) and the ability to transfer episomal DNA 
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(Mantel et al. 2013, Regev-Rudzki et al. 2013). In addition, it has been demonstrated that 
parasites are capable of exchanging genetic materials via EVs. 
In this study, different parasite strains, each containing separate drug resistance genes 
(WR99210 or blasticidin) and plasmids encoding different fluorescent markers were co- 
cultured. Interestingly, parasites were able to survive after exposure to both drugs and the 
next generation of parasites harbored both drug resistance genes and fluorescent marker. This 
transfer of plasmid was detected to occur through exosome-like vesicles secreted from the 
pRBCs. Moreover, this transfer of plasmid was seen to happen most effectively during early 
stage of the asexual life cycle (Regev-Rudzki et al. 2013). 
The result of this study suggested that drug resistance could be transferred to drug-sensitive 
iRBC thru EVs. Recently, data from in vitro studies have reported that EVs from P. 
falciparum infected RBCs act as messenger, create communication between parasites during 
asexual stages as well as directing the parasite generation into gametocytes. These data 
suggested that EVs seemed to be an important factor in the regulation of gametocytes 
commitment in P. falciparum (Mantel et al. 2013). Additionally, stimulation of cell-to-cell 
communication mediated by EVs also led to increased gametocytogenesis, suggesting that 
EVs from parasites might give a means of quorum sensing to activate gametocytogenesis 
(Guimaraes Sampao et al. 2017, Mantel et al. 2013, Regev-Rudzki et al. 2013). All these 
studies provide evidence that EVs or MPs secreted from pRBCs are involved in parasite-to- 
parasite and parasite to host cell communications and host immunoregulation (Campos et al. 
2010, Mantel et al. 2013, Wang et al. 2017). 
1.13 ARGONAUTE2 (AgO2) PROTEIN AND miRNA 
 
It has been reported that EVs derived from pRBCs have the ability to transfer cargo including 
protein and nucleic acids. Further in vitro studies found that EVs from P. falciparum pRBCs 
could affect host endothelial cells via transfer of functional microRNA, suggesting that 
Plasmodium might actively manipulate the host immune system through EVs or target host 
RBC and alter EVs for parasite invasion (Mantel et al. 2014). In other pathogens such as 
Epstein-Barr virus, the virus activates secretion of EVs that contain viral microRNAs from 
pRBCs, which can downregulate the expression of cytokine in uninfected monocyte-derived 
dendritic cells (Pegtel et al. 2010). 
In other systems, nucleic acid including messenger RNA and microRNA were found in the 
EVs which may be transported to and function in recipient cells. Recent studies have reported 
that human argonaute 2 (hAgo2) was found to bind to hundreds of miRNAs and these hAgo2- 
miRNA complexes were transferred into the parasites via EVs. PfEMP1 expression was 
downregulated by miR-451/140 through the latter’s binding to the A and B subgroups of var 
genes (a family of genes encoding PfEMP1) (Wang et al. 2017). The recent study 
demonstrated that hAgo2 in both EVs and parasites inhibits parasite development and that 
hAgo2-miRNA (miR-451/miR-140) complexes target several important P. falciparum genes 
that are involved in the pathogenesis of malaria (Wang et al. 2017). 
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The result of this study also revealed that the level of hAgo2 decreases when the parasitemia 
was higher than 1.5% and that human miR-451 and miR-140 can recognize the 5´or 3´ UTR 
of var genes at the transcriptional level, efficiently downregulating the expression of the 
luciferase reporter (Wang et al. 2017). These data implied that both miRNAs could be 
involved in the broad transcriptional regulation of all A and B subgroups of var genes. 
Furthermore, depletion of hAgo2 from RBCs can accelerate the development of P. falciparum 
parasites in culture, suggesting that miRNAs play an important role in the inhibition of 
parasite activities. miRNAs are noncoding RNAs of 19-24 nucleotides that originate from 
larger primary transcipts encoded in the genome. Argonaute-2 protein plays a crucial role in 
RNA-mediated silencing (RNAi) processes. Ago-2 binds to a short guide RNA including 
miRNA and short interfering RNA (siRNA) and are a vital component of the RNA-induced 
silencing complex (RISC) (Meister et al. 2004, Meister & Tuschl 2004). 
1.14 SINGLE CELL TECHNOLOGY 
 
Single-cell technologies allow for analyses at the individual cell level and are being used in 
different areas of biology and medicine. In recent years, single-cell RNA sequencing 
techniques have undergone rapid development and have become an important area of 
biomedical science (Nakamura et al. 2015). Traditional RNA sequencing usually involves a 
heterogenous population of cells, which mask the difference among individual cells 
(Geschwind and Konopka 2009), whereas single-cell RNA sequencing analyses will provide 
a finer-grained picture of biology complex and unmask heterogeneity that is present in cells. 
Furthermore, single-cell resolution is needed to discover more complicated mechanism in 
cellular development, confirmation of the distinct gene expression signature across different 
cell types, identification of the functional differences among the same cell type, evaluate 
effectiveness of the drug and identify markers of resistance to targeted drugs (Ho et al. 2018, 
Wang and Bodovitz 2010). Single-cell profiling methods will also allow researcher to 
uncover new and possibly unforeseen biological findings compare to traditional methods that 
assess bulk population. 
1.15 SINGLE-CELL GENE EXPRESSION ANALYSIS 
 
Recent advancements in single-cell gene expression in particular single-cell transcriptomics 
have contributed to the way researchers addressing unanswered questions concerning 
intracellular gene regulatory networks from a cell-centric viewpoint and bridging to the 
characterization of intercellular pathways which is masked in bulk analysis. Bulk RNA-seq 
expression profiles are the results of averaging over millions of cells that might differ widely 
(Figure 6). Populations of cells that have very similar cellular phenotypes may have different 
transcriptome profiles at the single cell level due to inherent biological heterogeneity, 
unsynchronized cell-cycle stages or stochastic transcription events (Grün et al. 2015). Single 
cell transcriptomics provide information on heterogeneity, prevalence and co-expression of a 
gene at the single cell level (Dalerba et al. 2011, Hashimshony et al. 2016, Grün et al. 2015). 
The first single-cell transcriptome analysis paper was published in 2009 demonstrating the 
possibility of scRNA-seq and the advantage of single cell microarrays in a mouse blastomere 
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study (Tang et al. 2009). High-impact studies using scRNA-seq have been growing rapidly 
in several fields and there has been rapid development in single cell technologies such as 
reducing noise, increasing sensitivity and specificity and in particular the throughput for 
single-cell transcriptomics (Kolodziejczyk et al. 2015, Islam et al. 2014, Picelli et al. 2013, 
Ramskold et al. 2012, Picelli et al. 2014,Picelli et al. 2014, Wilson et al. 2015). Several 
important features can be defined at the single cell level for the expression of each gene and 
more importantly gene expression patterns predicting a specific cell type including 
heterogeneity, prevalence and co-expression (Dalerba et al. 2011, Hashimshony et al. 2016). 
1.16 SINGLE CELL RNA SEQUENCING (scrRNA-seq) 
 
In the past decade, scRNA-seq has emerged following next generation sequencing (NGS) and 
since then it has revolutionized biological research. Typically, RNA-seq is performed in bulk 
and the data represent the averaged patterns of gene expression across millions of cells, which 
might mask biologically relevant differences in gene expression among cells (Olsen et al. 
2018). Single-Cell RNA-seq can overcome this problem. Numerous protocols have been 
developed for scRNA-seq including STRT (Islam et al. 2011), Smart-Seq (Ramsköld et al. 
2012), CEL-Seq and CEL-Seq2 (Hashimshony et al. 2012 & 2016), Smart-seq2 (Picelli et 
al. 2013), Quartz-Seq and Quartz-Seq2 (Sasagawa et al. 2013 & 2018) MARS-Seq (Jaitin et 
al. 2014), SCRB-Seq (Soumillon et al. 2014), Drop-Seq (Mackosko et al. 2015) and SPLiT- 
seq (Rosenberg et al. 2018). 
scRNA-Seq provides many valuable insights into biological complex system, ranging from 
cancer genomics to diverse microbial groups. Single-cell RNA sequencing enables researcher 
to address questions about heterogeneity that are inaccessible using methods that average over 
bulk cell extracts. It can uncover rare and complex cell populations and reveal regulatory 
relationships among genes and it makes possible to measure the absolute numbers of RNAs 
including short RNA molecules in a cell. It can also detect large numbers of small RNAs such 
as miRNA as well as tRNA and snoRNA whose function is still unknown (Segerstolpe et al. 
2016). Single-cell RNA/DNA sequencing provides a higher resolution of cellular differences 
and understanding of the function of individual cells. 
The main shortcomings in scRNA-seq include the increased levels of noise in the measured 
transcript abundances, unnecessary transcript dropout rates, stochastic bursting events in 
scRNA-seq data generating abundant nondetections, high variability, and complex expression 
data distribution (Ho et al. 2018). Hence, it is crucial to differentiate high noise and low- 
quality samples, which are degraded during preparation of the library or poorly, amplified 
(Ho et al. 2018). Bulk sequencing can only capture 1% of the cell population. The main 
disadvantage of single cell sequencing is that it is more challenging to perform in comparison 
with bulk sequencing (Shintaku et al. 2014). Although the single-cell technology has been 
expanding rapidly, there is still a number of issues that deserve careful consideration such as 
inefficient synthesis of full-length cDNAs by reverse transcription (Kalisky and Quake 2011, 
Kolodziejczyk et al. 2015). 
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Fig. 6. The illustration of the averaging effect. Transcriptomes of mRNA from population 
of cells (left) that includes several types of cell is subjected to an averaging effect in which 
mRNA data from multiple cells are averaged. This averaging effect results in the dilution of 
mRNA species which are only present in a subset of cell transcripts (pink and black). In 
contrast, transcriptomes of mRNA from single cells (right) exactly report the abundances of 
each mRNA specie relative to other mRNA species in that particular cell. 
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2 AIM 
Specific Aims: 
Paper I 
To investigate if antimalarial drugs such as AQ, CQ, DHA and PPQ could 
cause random DNA damages in the malaria parasites and that the gene pools of 
a parasite population can be rapidly diversified through an erroneous repair 
mechanism. 
Paper II 
 
To elucidate if EVs derived from iRBC can traffick miRNAs to target cells and 
regulate their gene expression. 
Paper III 
 
- To develop and enhance workflow for individual pRBCs isolation and Single - 
Cell RNA-seq library preparation from intra-erythrocytic developmental cycle 
stages of P. falciparum parasites. 
- To elucidate Single-Cell RNA-sequencing for molecular analyses of rare P. 
falciparum phenotypes as well as characterization of sub-stages of the 
intraerythrocytic developmental cycle and gene marker that distinguish between 
asexual and sexual stages of individual P. falciparum parasites. 
- Identification and differentiation of genes from variable genes families at 
single cell level. 
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3 RESULTS AND DISCUSSION 
Paper I 
 
Antimalarial drugs and DNA damage response in Plasmodium falciparum 
 
The emergence of highly drug-resistant parasites poses a central problem in malaria 
eradication. P. falciparum DNA is subject to high levels of genotoxic insults during its complex 
life cycle within the human host and mosquito vector. DNA damage response in P. falciparum 
is thought to contribute to many crucial biological functions of malaria parasites. Since the 
DNA repair machinery are essential in the maintenance of genome integrity and affect 
organismal genome mutation rates, they may serve as a potential source for the generation of 
drug resistance. Most of the components of the DNA repair system are conserved in the parasite 
genome. 
In this study, we investigated if antimalarial drugs such as AQ, ATS, DHA, CQ, and PPQ cause 
random DNA damages in the parasites and that the gene pool of a parasite population can be 
diversified via incorrect repair mechanism. 
We initiated the study by determining the IC50 of these drugs and assessed if these drugs can 
cause random DNA damage in the parasite. We then treated the parasites with these drugs at 
different doses and incubated for 12h and 24h. To evaluate DNA damage, we used a comet 
assay based single-cell electrophoresis to quantify the extent of DNA damage expressed as 
Olive Tail Moment values, with higher values implying greater DNA damage. ATS and DHA 
were used as positive controls. All parasites showed evidence of nuclear DNA damage after 
12h and 24h post- exposure to drugs, suggesting that all drugs tested can induce DNA breaks. 
Noteworthy was the high level of DNA damages detected after 12h of exposure to AD, ATS, 
and DHA and after 24h of exposure to CQ and PPQ, suggesting that CQ and PPQ may confer 
a delayed effect. This observation cannot be generalized since AQ, which is also a quinoline 
analog, causes a similar effect to ART derivatives such as ATS and DHA. To confirm our 
results, parasites were also evaluated in the comet assay after gamma irradiation exposure at 
65Gy, which is known to cause DNA double-strand breaks. As we predicted, parasites exposed 
to gamma irradiation also displayed comet-tails like with OTM value comparable to parasites 
exposed to drugs. Our results showed that both quinoline and artemisinin-derived compounds 
could induce DNA damage in the parasite genome. 
It has been reported that ART and ATS induced DNA damage by increased free radical 
formation via the generation of ROS (Gopalakrishnan et al. 2015, Cumming et al. 1997). We 
next investigated if DNA damage caused by these drugs is mediated by intracellular ROS. We 
measured the amount of intracellular ROS using DCF-DA fluorescence assay. We found that 
all tested drugs resulted in the increase of intracellular ROS level after six hours of exposure. 
Furthermore, most drugs caused the maximum peak of ROS production after 12 hours. 
Remarkably, the levels of intracellular ROS declined from the peak levels between 12- and 24- 
hours post-exposure except for CQ and PPQ, in which further increase in intracellular ROS 
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levels was observed, suggesting that CQ and PPQ had delayed effect in the parasites. This 
observation was coherent with the results obtained in the comet assay. The decreased 
intracellular ROS levels at 24-hour post-treatment may also indicate that most parasites were 
killed after exposure to drugs. In addition, dose-dependent increases in ROS levels were only 
seen in CQ and PPQ treated parasites but not in AQ, ATS, and DHA. The results from this 
assay gave an association between drugs-mediated DNA damage and the induction of ROS. 
Glutathione (GSH) pathway plays a crucial role in the detoxification of intracellular ROS and 
ferriprotoporphyrin IX in Plasmodium. We then investigated if drug treatment could affect the 
GSH levels in the parasites. Indeed, total GSH levels were decreased in all drug-treated 
parasites and a parallel increase in GSSG (oxidized form of GSH) levels was observed. 
However, the increases in oxidized GSH were less obvious than the reduction in GSH levels. 
This observation indicated that the amount of the free GSH may also be reduced via formation 
of GSH-protein adducts. Low GSH: GSSG ratio is believed to be a marker of oxidative stress. 
The GSH: GSSG ratio in all drug-treated parasites was lowered compared to non-treated 
parasites, suggesting that these drugs induce oxidative stress in the parasites. 
Next, we sought to investigate whether a transcriptional cascade receptive to DNA damage 
would be upregulated by exposure to these drugs. We selected a group of DNA repair genes 
involved in different DNA repair pathways. This selection was based on previous reports as 
well as their sequence homology to known eukaryotic and yeast model organisms. Indeed, our 
results showed up-regulation of the DNA repair gene expression involved in different DNA 
repair pathways 12 and 24 hours post-treatment. Interestingly, some of the DNA repair gene 
expression levels differed among drugs, likely attributed to the type and the quantity of DNA 
damage induced by these drugs. Up-regulation of DNA repair genes involved in the HR 
pathway implied that these drugs induced DNA DSBs in the parasites, as DSBs are usually 
repaired via HR, MMEJ/A-NHEJ, and NHEJ. Orthologs of DNA repair genes involved in the 
NHEJ pathway are absent in the parasite genome. Mismatch repair genes encode proteins 
accountable for repairing errors that occurs during DNA replication (Mulligan et al. 2001). 
MMR proteins identify these errors and form a protein complex and eliminates the mismatched 
bases and subsequently corrects the sequence. Interestingly, we observed an up-regulation of 
DNA repair genes involved in mismatch repair pathways, suggesting that there was a mismatch 
resulting from faulty DNA repair. This error in the repair implied that drugs might induce DSBs 
in the parasites, which use an error-prone A-EJ/MMEJ pathway to repair DNA DSBs. 
All of the results supported our hypothesis that antimalarial drugs induce DNA damage in 
malaria parasites. It has been reported that defective DNA repair is associated with increased 
mutation rates and rapid development of drug resistance in P. falciparum (Trotta et al. 2004). 
We therefore tested further our hypothesis that antimalarial drug-induced DNA damages and 
subsequent erroneous repairs can accelerate the rates of mutation and hence the generation of 
drug resistant trait. We performed whole genome shotgun sequencing to search for functional 
consequences in the parasite genome after short exposure to antimalarial drugs. 27 parasite 
clones were successfully sequenced yielding a mean coverage of 56X. The genetic variation 
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background between the parental 3D7S21 clone (four untreated control parasite cultures) and 
the reference 3D7 were first assessed. Our results revealed that 3D7S21, which was cloned 
from 3D7 population cultured for a long period of time, seems to harbor > 3000 genetic 
variations from the reference 3D7 genome. Although the total numbers of called variants 
differed among control cultures, they were sufficiently comparable to each other since variant 
calling by false discovery rate can result in an increased type 1-error rate. Interestingly, the 
number of total variants found among clonal parasites originated from the same drug treatment 
can quickly result in an increase in variance in the genome in a parasite population. Provided 
that the period of the drug exposure was relatively short, the observed genome variance is 
unlikely to be a selection process driven by drug pressure but that each individual clone 
parasites could be subjected to random DNA damage and defective DNA repair. To further 
support the potential clonal variance driven by drug treatment, a principal component analysis 
of the genome sequences was done. Our results revealed that control parasites were tightly 
clustered while most drug-treated parasites did not cluster with their counterparts originated 
from the same drug treatment condition. Additionally, recovery cloned parasites were more 
divergent from the control parasites when comparing with the populations. We then calculated 
the proportion of variants located in the subtelomeric regions to further elucidate these 
individualized effects of the drugs. We found that drug-treated parasites showed wider range 
of the calculated proportions, confirming our observation that drug treatment had pushed 
genome divergence as seen by the altered variants distribution in the genome. A higher indel 
to SNP ratio were also seen in the parasite genome after exposure to drugs compared to the 
untreated parasites, except for PPQ. The manifestation of an indel is more likely to have 
resulted from defects in DNA repair of DSB site, thus higher indel to SNP ratios may imply 
that these drugs induced DSB in the parasites. This result was consistent to our results obtained 
from qRT-PCR experiments. Finally, we identified all indel variants that resulted in frameshift. 
In particular we saw at least one frameshift that occurred in a predicted DNA repair gene, which 
may result in inefficient in repair the DNA damage, destabilization of the parasite genome, and 
increased mutation rate in the parasite clone. 
Paper II 
 
Extracellular vesicles are important for cell-to-cell communications between parasites but EV’s 
effect on host cells still remains largely undetermined. In rodent and human malaria system, 
EVs can induce innate immune system of the cells (Mantel et al. 2013, Couper et al. 2010). It 
was also showed that EVs enable cell- to-cell communication among pRBCs through the 
transfer of the signaling substances from a donor to a recipient iRBC. This type of cellular 
communication is thought to be associated with the development of gametocytes (Mantel et al. 
2013). Moreover, it was also showed that EVs derived from pRBCs are effectively engulfed 
by macrophages and produce a strong inflammatory response. pro-inflammatory cytokines and 
chemokines generation leads to activation of endothelial cells and consequently recruit and 
infiltrating inflammatory cells, which then cause additional activation of endothelial cells and 
parasite sequestration. In addition, the analysis of pRBCs-derived EVs content discovered a 
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set of specific proteins from RBC and parasite and RNA such as small RNA species (Mantel 
et al. 2013). 
In this study, we aimed to elucidate the theory that EVs derived from iRBC contain 
microRNAs that can modify the recipient cells gene of target. We previously showed that 
purified EVs contained specific proteins from the parasite and host such as hAgo2 and RNA 
from EVs derived from pRBCs, even though the nature and function of these RNA species in 
malaria are not clear (Mantel et al. 2013). In order to confirm our results, we then elucidate the 
nucleic acid composition in EVs by analyzing the size distribution of RNA from purified EVs 
derived from pRBCs. We found small RNA species approximately 21-25 nucleotides which 
signify the occurrence of mature microRNAs. Although Plasmodium parasites don’t have 
functional RNA interference machinery that can produce miRNAs (Baum et al. 2009), we 
sought to investigate if these miRNAs came from the host. It was previously illustrated that 
RBCs from humans express a panel of miRNA with different function upon maturation of the 
RBCs (Chen et al. 2008). We then defined the content of human miRNAs in pRBCs-derived 
EVs using nanostring expression array that contain probes for all 800 miRNAs species derived 
from human and compared the contents and the number of human miRNAs from RBCs, 
pRBCs as well as EVs. Indeed, we detected a total of 21 RBC-specific miRNA in RBC and we 
also found several of these miRNA in pRBCs and pRBCs-derive EVs. We found out that all 
the miRNA were reduced in pRBCs and EVs except for miR-451 and let-7b as compared with 
RBCs. miR-452 is abundantly expressed in RBCs and plays a significant role in erythroid 
homeostasis upon maturation of RBC (Patrick et al. 2010). We also confirmed the presence of 
mature miR-452a, let-7b, RNU6, and miR-106b in RBCs, pRBCs and EVs using northern 
analysis. All four miRNA were detected in RBCs and EVs derived from pRBCs. Overall, our 
results revealed the presence of RBC-derived miRNAs, specifically miR-45a, in both EVs and 
pRBCs. 
There is growing evidence that shows that EV-mediated miRNAs transfer among cells. We 
then postulated that this subset of miRNA found in both pRBCs and EVs may bind to Ago2. 
Although the function of in erythroid cells has been described (Lawrie et al. 2010), there is still 
no evidence that shows if the RNAi machinery still functional when erythroid cells differentiate 
to normocytes or mature erythrocytes. To determine further if these functional miRNAs were 
present in mature erythrocytes, we investigated the expression of the RNAi machinery 
components from hematopoietic stem cells to normocytes during in vitro RBC development 
(Bei et al. 2010). Ago2 was detected in mature erythrocytes, whereas Drosha, as well as Dicer 
were only observable in erythroid cells, before anucleation. We further investigated the Ago2 
localization in mature erythrocytes by immunofluorescence assay and FACS. In mature 
erythrocytes, Ago2 was localized to the membrane peripheral. Similar results were found in 
pRBCs that contain ring stage of parasites (up to 20 hpi), but, the signal disappears during the 
late cycle of pRBCs. We revealed that miR-451a and let-7b formed an active complex with 
Ago2 in EVs. Our results also confirmed the presence of Ago2 in the soluble fractions that 
represent RBC cytosol and food vacuole by western blot analysis. The protein was detected in 
the pellet fraction during the 24 h of parasite development which also confirmed the 
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observation in IFA localization assay in the parasite and at peripheral RBC membrane and/or 
cytoskeleton. 
Human Ago2 and stomatin were also found in EV-derived from pRBCs by western blot 
analysis, confirming our previous proteomic results (Mantel et al. 2013). Our study revealed 
that Ago2 is present in EVs through immuno electron microscopy. Recent studies have shown 
that almost all miRNAs detected in the healthy donor’s plasma are usually linked with the 
protein-lipid complexes and not with EVs (Arroyo et al. 2011). We used size exclusion 
chromatography and Proteinase K protection assays in order to eliminate the probability that 
Ago2 and miRNA are serum-derived residual complexes. Our results showed that serum from 
human certainly has a subpopulation of miRNAs and proteins as those from EV preparations. 
Ago2 resisted to Proteinase K treatment with the purified EVs suggesting they are protected 
inside the EVs from protease (Mantel et al. 2013). Our results confirmed that human Ago2 and 
miRNA are present inside EVs. 
In order for miRNAs to be functional, it has to complex with Ago2 to form RISC. RISC binds 
to the targeted mRNA via the seeding sequence of the miRNA. We further investigate if this 
complex form a functional silencing complex. We tested the sequence-specific endonucleolytic 
activity of RISC by incubating purified pRBCs-derived EV with a radioactively labeled RNA 
sensor probe that contain a complementary sequence to either miR-451a or let-7b. This 
preliminary experiment revealed a time-dependent cleavage activity. We further quantify the 
activity of EV lysate and determined the concentration of the probe during of specific cleavage 
of the miR-452a probe. We found that the probe was fully degraded at higher concentrations, 
indicating the nonspecific RNases in the EV lysate. We also showed the importance of active 
enzyme by treating the EV lysate with Proteinase K or EDTA. To further corroborate the Ago2- 
miRNA complex (RISC) functionality in EVs, HEK293 cells were transiently transfected with 
a constructed reporter gene. We found that the luciferase assay with the miR-451a target 
sequence in the 3′-UTR of a reporter cassette showed that the activity of the reporter gene was 
substantially downregulated in transfected HEK293 cells upon incubation with EVs. 
Supplementation of either let-7b or miR-15a of miR-106a responsive element showed a 
substantially depleted the luciferase reporter gene activity, even in the absence of EVs, 
suggesting that HEK cells express a substantial amount of those miRNAs. Our results revealed 
that miRNAs in EVs are functional and Ago2 association is vital for activity. 
Confirmation of the occurrence of functional miRNA-Ago2 complexes in EVs, we set to 
elucidate the miRNA-Ago2 complexes physiological function during infection. We previously 
reported that EVs were internalized in pRBCs and macrophages (Mantel et al. 2013). To 
investigate if EVs are able to internalize in endothelial cells which may contribute to the 
changes in the function of endothelial cells during infection, we labeled the membrane of 
purified EVs and subsequently co-incubated with BMEC (Schweitzer et al. 1997). We detected 
an increase in the uptake of labeled EVs and confocal microscopy analysis also verified the 
increase of labeled EVs in the perinuclear region of endothelial cells. We further determine if 
the uptake of pRBCs-derived Evs into BMEC is through endocytosis. We also tested with 
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known endocytosis inhibitors (Mulcahy et al. 2014) to measure uptake of EVs over time. Our 
results confirmed that EVs were internalization in endothelial cells via endocytosis. We also 
found that EVs are capable of activating pro-inflammatory cytokines including IL-6 and IL-1 
which lead to increase expression of adhesion molecules (Rabb et al. 2002), therefore 
contributed to the vascular dysfunction by activating an excess leukocyte adhesion and 
transmigration. Additionally, the internalization of EVs directly activates VCAM-1 expression 
possibly intensifying vascular dysfunction. 
We further investigated if EVs derived from pRBCs may transport regulatory miRNAs to the 
endothelial cell. We determined miR-451a levels in endothelial cells upon EV internalization 
using qRT-PCR. Our results showed an accumulation of miRNA in a dose-dependent manner 
approximately up to the 50-fold above background. We also identify and quantify copy number 
of miR-451a in endothelial cells during uptake of EV through RNA fluorescent in situ 
hybridization (RNA FISH). We further treated BMEC with α-amanitin before addition of EVs 
to eliminate the probability that miR-452a expression is activated in endothelial cells upon 
uptake of EV instead of transferred via EVs and demonstrated that the increase in the 
expression of miR-451a was not affected by α-amanitin. Overall our experiments revealed that 
miR-451a can be transferred to endothelial cells through EVs, and it was not expressed in 
endothelial cells. 
We then investigated if internalized EVs can target the gene expression in endothelial cells via 
RNA interference of EV-derived miRNA complexes on target genes. We used miR-451a target 
gene prediction search tools. Our result revealed multiple targets either within coding regions 
of genes or within the 3´-UTR of genes. We subsequently established the expression of these 
putative targets in the BMEC line through microarray expression analysis. In order to evaluate 
possible expression regulation by EV-derived miRNAs in BMEC, we focused on the 
previously validated miR-451a targets including CAV-1, ATF2, GRSF1 and PSMB8 (Orom et 
al. 2012, Trajkovski et al. 2011, Lv et al. 2014, Lopotova et al. 2011), all of which are expressed 
above the median of all genes in this BMEC line. miR-451a has been shown to inhibit ATF2 
expression through binding to its 3′-UTR (Lv et al. 2014). ATF2 is a cAMP-response element- 
binding protein with a basic leucine zipper (bZIP) domain, through interactions with other bZIP 
proteins (Lv et al. 2014). This protein activates an array of genes that are involved in anti- 
apoptotic signaling (Bhoumik et al. 2004), and inhibition of this protein through siRNA causes 
apoptosis in a melanoma model (Bhoumik et al. 2002). ATF2 downregulation by miR-451a 
might consequently add to the detected apoptosis of endothelial cells upon infection (Hemmer 
et al. 2005). Quantification of transcript levels by qRT-PCR in endothelial cells upon EV 
incubation compared to control showed  significant  downregulation of two markers, CAV-  1 
and ATF2 (both with partial miR-451a target sites in their 3′-UTR) after 24h of EV incubation 
compared with untreated control cells. GRSF1 and PSMB8 gene expression were not affected 
during EVs incubation. Caveolin-1 (CAV-1 ), a scaffolding protein and key component of 
caveolae, particular lipid rafts in the plasma membrane of many cell types with a function in 
signal transduction and endocytosis (Bastiani et al. 2010). Western blot analysis showed the 
downregulation of both CAV-1 and ATF2 on the protein level after EVs incubation. Our 
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studies have shown that pRBCs-derived EVs be able to regulate gene expression in the 
recipient endothelial cells. Particularly, we showed that miR-451a derived from EVs targets 
endothelial cell expression markers including ATF2 and CAV-1. 
To confirm further that CAV-1 and ATF2 downregulation is facilitated by miR-451a derived 
from EVs, two different approaches were used. BMEC was transduced with lentiviral 
expression vector containing miR-451a or GFP for control. Our results showed that in the 
BMEC/miR-451a line miR-451a was highly activated while CAV-1 and ATF2 expression on 
both the transcript and protein levels were decreased, compared to the GFP control 
(BMEC/GFP) and BMEC. We then transiently expressed Sponge miR-451a in endothelial cells 
before incubation with EVs to confirm the targets of miR-451a derived EVs. We found that 
Sponge miR-451a binds and sequesters cellular target miRNAs and thus neutralizes them. We 
also revealed that the expression of Sponge miR-451a restored the expression of CAV-1 and 
ATF2 on the mRNA and protein levels and verifies that they are the target of miR-451a-derived 
Evs. We were able to repeat the detected effect of EVs on endothelial barrier properties in the 
BMEC/miR-451a line thru permeability assays using rhodamine-labeled dextran. Our 
experiments verified a regulatory function miRNA-derived EVs-complexes in endothelial gene 
expression and barrier function. 
In summary, data obtained from this study showed that EVs derived from pRBCs contain host 
miRNAs that form a functional RISC complex with Ago2. We also demonstrated that EVs 
were effectively internalized in endothelial cells, where the miRNA-Ago2 complexes modify 
target gene expression and barrier functions. The data gained from different in vitro 
experiments support a model where EV release adds to both local and systemic pro- 
inflammatory cytokines and chemokines generation and to vascular dysfunction which 
stimulates endothelial induction, leakage, and sequestration of parasites including pathology 
upon malaria infection. Moreover, our results give a mechanistic association between EVs and 
vascular dysfunction upon malaria infection. 
Paper III 
 
The ability to measure gene expression of individual P. falciparum parasites gives us an 
opportunity to answer key questions that involve small sub-populations of P. falciparum 
parasites, including mechanism triggering the switch from asexual to sexual development 
which may help to identify targets for transmission-blocking agents, artemisinin-induced 
dormancy in resistant parasites and mechanism underlying chloroquine resistance, with 
important implications for malaria treatment. P. falciparum parasites display cellular plasticity 
during their complex life cycle. Malaria clinical symptoms result from asexual replication 
within erythrocytes, while transmission to new hosts depends on replication in the mosquito 
vector. Both transmission and development of malaria disease are therefore supported by the 
malaria parasite´s capability to successively differentiate into morphologically distinct forms, 
such as invasive, replicative and gametocytogenesis (sexual stages). This adaptability is 
orchestrated by tight regulation of the P. falciparum genome, in which the functions of most 
genes are still not well understood (Otto et al. 2014). Insight into gene use and gene function 
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during the P. falciparum parasite´s complex life cycle will help to identify targets for new drugs 
and transmission-blocking agents. 
In this study, we investigated the capacity of Single-Cell RNA-seq for molecular analyses of 
rare P. falciparum parasites phenotypes. We sought to establish a capillary-based iRBC method 
in isolating individual pRBCs followed by Single-Cell RNA-seq using Smart-Seq2. We picked 
individual pRBCs at six different time points during the 48h intraerythrocytic development 
cycle over three separate experiments. Our result showed that although we tightly synchronized 
the parasites, the clustering of individual-parasite transcriptomes is not completely aligned. 
This may be due to difficulties in visually distinguishing the intermediate IDC stages using 
10X magnification when picking single parasites. Higher magnification is indeed needed in 
order to specifically verify the morphological differences of cells. However, when we 
performed computational analyses, we could designate a group of parasites to distinct IDC 
stages. 
It was demonstrated that scRNA-seq lacked sensitivity with regard to gene detection 
(Ramsköld et al. 2012) and population-level analyses of the ring stage of the 48h IDC have 
revealed the small amount of RNA present in the ring stage and also inadequate transcriptional 
activity (Sims et al. 2009). In our single-cell result, we were able to identify the sub-stages of 
IDC of P. falciparum especially during the early stages of the IDC and a gene marker that 
distinguishes among asexual and sexual parasite stages by transcriptionally profile the 165 
individual pRBCs at different time points during IDC. We identified a minor population of 
putative gametocytes based on a single genetic marker. We also established numerous RNA- 
seq libraries from populations at each time points as control. The average numbers of P. 
falciparum genes detected were 300-800 in every single pRBCs, similar to two current 
published Single-Cell RNA-seq data sets (Poran et al. 2017, Reid et al. 2018). 
Assessment of the overall structures in individual P. falciparum parasite transcriptomes using 
principal component analyses and t-distributed stochastic neighbourhood embedding shown 
that individual pRBCs displayed heterogeneity. Furthermore, we investigated the 
transcriptomes of each single pRBCs and concentrated on their expression of a previously 
known data set of gene during IDC in P. falciparum (Bozdech et al. 2003). We identified genes 
with significant differential expression in most sub-populations. For example, SP1 and SP6 
showed the difference in expression of 42 genes that involved in cytoplasmic translation 
machinery in SP1 on the other hand SP6 early rings and merozoite invasion transcripts and also 
actin myosin related genes were up-regulated. Though we observed a large number of dropouts 
in single-cell data due to little amount RNA presence, we still found that the pattern of gene 
expression followed the temporal pattern of expression as described previously (Bozdech et al. 
2003). 
In order to assess the detection capacity of rare parasite phenotypes in cell population, we then 
investigated the RFP expression (164-tdTom express RFP under the PF10_0164 promoter) 
(Buchholz et al. 2011) in the transcriptome profiles. This promoter is induced when parasites 
become gametocytes stages. We discovered expression of RFP in three single pRBCs and 
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identified several known gametocyte markers. Interestingly, characterization of the putative 
gametocytes found novel putative gametocyte genetic markers with substantial increased 
expression in the RFP expressing cells. Validation of ten gametocyte specific genes with high 
expression in RFP-expressing single cells using qRT-PCR showed that five of ten consistently 
had higher levels of expression among stage I and mid-stage gametocytes compared to schizont 
stage parasites. Our results demonstrated that it is possible to molecularly identify rare parasite 
phenotypes using Single-Cell RNA-seq and functional study of these candidate gametocyte 
markers will determine if they are crucial to P. falciparum gametocyte development or sexual 
stage commitment, which will also help to design a transmission-blocking strategy. 
P. falciparum contains var, stevor and rif gene families that code for proteins known as P. 
falciparum erythrocyte membrane protein 1 (PfEMP1), sub-telomeric variable open reading 
frame (stevor) and repetitive interspersed family (rifin), respectively (5, 124-130). Variable 
gene families (var genes) are clustered towards the telomeres and code for proteins that are 
transported to the surface of pRBCs where they mediate adherence to host endothelial receptors 
(131), resulting in the sequestration of infected cells in a variety of organs. These properties are 
important virulence factors which contribute to the development of severe malaria (132-135). 
Transcriptional switching among var genes enables antigenic variation and is a means of 
immune evasion, enabling chronic infection and transmission (136). Thus, var gene family 
products play a crucial role to the pathogenesis of malaria and to the production of protective 
immunity. We therefore investigated the feasibility of analyzing expression of the var gene 
families at single cell-level, we carried out targeted analysis of var and clag genes which are 
involved in erythrocyte invasion and cytoadhesion. We confirmed that clag 3.1 and clag 3.2 
genes are dominantly expressed in a considerably larger number of parasites and dual- 
expression of these genes in a few individual parasites. We also verified the dominant 
expression of var gene in three single cells including UPSC1, UPSB1 and UPSB6 and UPSB7. 
Var2csa gene, which is involved in pregnancy-associated malaria, was found expressed in one 
single cell. 
Moreover, we showed that our technique has the capacity of facilitating differential gene 
expression analyses from the var gene families in P. falciparum parasites at the single cell level. 
Recent study have showed that smart-seq2 oligo-dT modification (Reid et al. 2018), yielded a 
positive effect on the total coverage of genes expressed in late intraerythrocytic developmental 
stage. It is interesting to further scrutinize if this modification of poly-T oligo will also increase 
yields in the ring stage of P. falciparum IDC parasites. Lastly, we have developed and evaluated 
a strategy for global transcriptional profiling of P. falciparum at single-cell level. This strategy 
can be useful in elucidating at the cellular level the molecular basis of malaria disease. It could 
also be used for other Plasmodium species and other members of the Apicomplexa including 
Babesia, Cryptosporidium parvum and Toxoplasma gondii. 
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4 CONCLUSION AND FUTURE PERSPECTIVES 
The development of drug resistance in P. falciparum has compromised the efficacy of 
antimalarial drugs. Emerging multidrug resistance to current drugs poses a central problem in 
global malaria control. Identifying the causes of drug-resistant malaria seems to be more 
complex than perhaps originally predicted. The lack of clear understanding of the molecular 
mechanisms underlying antimalarial drug action and drug resistance, commitment to 
gametocytogenesis, and parasite-to-parasite communications hinders efforts to eradicate 
malaria. This thesis attempted to answer some of those questions stated above. 
 
 
I) There are still a lot of unanswered questions concerning the DNA repair mechanism and 
the important of different DNA repair genes involved in these pathways in P. falciparum. 
One major factor that contributes to the resistance development is the high plasticity of 
the parasite genome that permits the rapid acquisition and fixation of adaptive mutation, 
gene-duplication and deletion upon exposure to antimalarial drugs. Although the causes 
of high plasticity in the parasite genome are not well understood, DNA repair 
mechanisms as well as the overall DNA damage response are believed to contribute to the 
maintenance of the genome integrity and genome mutation rate. In Paper I, we tried to 
investigate the effect of antimalarial drug on the genome integrity in P. falciparum and 
the possible role of DNA repair mechanism in the development of resistance to 
antimalarial drug. We revealed direct and indirect evidence of DNA damages in parasites 
after short exposure to all the tested antimalarial drugs. Genome sequencing revealed that 
some of these DNA damages were likely repaired by an error-prone DNA repair 
mechanism. Thus, even short exposure to antimalarial drugs could lead to novel 
mutations and diversify the gene pool in a population, potentially allowing for selection 
of drug resistant parasites. Further studies are needed to understand the mechanisms 
affecting mutation rate, the role of DNA repair processes as well as the presence of indels 
in DNA repair genes. These studies may provide insights on drug design for malaria 
treatment and development of new strategies to effectively prevent drug resistance. 
 
 
II) Cell to cell communication is believed to be essential for cell survival, differentiation, and 
control of population density. P. falciparum infected erythrocytes directly communicate 
with one another using extracellular vesicles (EVs) that are capable of delivering protein, 
lipid, messenger RNA and microRNA, as well as pathogenic molecules and antigens. 
EVs are also involved in several physiological processes such as immune regulation. 
Human Argonaute 2 (hAgo2) is an effector protein that binds to microRNAs to form 
RISC. The sequence-specific miRNA directs this RISC complex by targeting the coding 
region sites of target mRNAs for endonucleolytic cleavage and/or to the 3´-untranslated 
regions (UTR), resulting in repression in translation. In this study, we detected several 
miRNA from the host in EVs derived from pRBCs and revealed that these miRNA were 
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bound to human Ago2 and formed functional complexes. Furthermore, the internalization 
of iRBC-derived EVs into endothelial cells was observed. These Ago2-miRNA complex- 
containing EVs were shown to modify target gene expression and alter endothelial barrier 
properties. Overall, our discoveries give a mechanistic link between EVs and vascular 
dysfunction that promote endothelial activation and parasite sequestration during malaria 
infection. In the future, it will be important to determine the role of EVs in gametogenesis 
and also the spread of resistant traits. 
 
 
III) Single-cell genomic is a powerful technique that has helped unravel the dynamic of 
genetic changes within the population and the genetic structure of unicellular organisms. 
Single-cell RNA sequencing of P. falciparum could be key to understanding the 
complexity of malaria infection. We developed and assessed a technical platform that 
enables single-cell transcriptomic analysis of individual P. falciparum parasites. In this 
study, we identified a minor population of gametocytes with distinct gene expression 
signatures, a sexual stage parasite based on a single genetic marker. We also showed huge 
heterogeneity in transcript profiles among highly synchronized parasite populations. Our 
method showed the capacity to elucidate the transcriptional programs underpinning rare 
phenotypes from single parasite level. Furthermore, we proved that the coverage of the 
sequence was adequate to generate lists of important genes based on global differential 
expression analyses. This platform will allow future studies to further explore the 
mechanism by which the parasites switch and commit to sexual development. 
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